fluconazole and Aspergillosis studies

Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.

Research Excerpts

Excerpt	Relevance	Reference
"5 mg/kg twice daily; N=248) with fluconazole oral solution or capsules (400 mg daily; N=246) in 494 patients with anticipated profound neutropenia (i."	9.12	An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. ( Andreesen, R; Bertz, H; Bodenstein, H; Boewer, C; Cornely, O; Dölken, G; Glasmacher, A; Hänel, M; Junghanss, C; Pasold, R; Ullmann, AJ; Wandt, H; Wedding, U; Wolf, HH, 2006)
" We performed a randomized trial to compare itraconazole vs fluconazole, for prevention of IFIs in patients with acute leukemia (AL) and HSCT recipients."	9.12	A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. ( Akria, L; Benyamini, N; Dally, N; Dann, EJ; Fineman, R; Gorelik, A; Haddad, N; Oren, I; Rowe, JM; Sprecher, H; Tamir, A; Zuckerman, T, 2006)
"In an international, randomized, double-blind trial, we compared oral posaconazole with oral fluconazole for prophylaxis against invasive fungal infections in patients with graft-versus-host disease (GVHD) who were receiving immunosuppressive therapy."	9.12	Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. ( Boparai, N; Chandrasekar, P; Durrant, S; Greinix, H; Langston, A; Lipton, JH; Morais de Azevedo, W; Patino, H; Pedicone, L; Reddy, V; Tarantolo, SR; Ullmann, AJ; Vesole, DH, 2007)
"To compare the benefits and harms of voriconazole with those of amphotericin B and fluconazole when used for prevention or treatment of invasive fungal infections in cancer patients with neutropenia."	8.90	Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia. ( Dalbøge, CS; Gøtzsche, PC; Johansen, HK; Jørgensen, KJ, 2014)
" Terms such as micafungin, aspergillosis, zygomycosis, invasive fungal infections, emerging fungal infections, antifungal treatment or therapy, antifungal prophylaxis, empiric or pre-emptive therapy were crossed."	8.85	[Future role of micafungin in the treatment of invasive mycoses caused by filamentous fungi]. ( Salavert-Lletí, M; Zaragoza-Crespo, R, 2009)
"To compare the benefits and harms of voriconazole with those of amphotericin B and fluconazole when used for prevention or treatment of invasive fungal infections in cancer patients with neutropenia."	8.83	Voriconazole versus amphotericin B in cancer patients with neutropenia. ( Gøtzsche, PC; Johansen, HK; Jørgensen, KJ, 2006)
"To investigate the therapeutic role of topical and oral fluconazole treatment using a rabbit model of Aspergillus fumigatus keratitis."	7.72	Comparison of efficacy of topical and oral fluconazole treatment in experimental Aspergillus keratitis. ( Avunduk, AM; Beuerman, RW; Greer, D; Kaufman, HE; Warnel, ED, 2003)
"Due to an increasing number of leukemic patients with invasive gingival aspergillosis during neutropenia (neutrophils <500 cells/microl for >10 days), we evaluated the efficacy of oral itraconazole prophylaxis for preventing this invasive infection at our hospital."	7.71	Itraconazole prophylaxis for invasive gingival aspergillosis in neutropenic patients with acute leukemia. ( Fujihara, M; Kyo, T; Mikami, Y; Myoken, Y; Sugata, T, 2002)
"The efficacy of fluconazole against Aspergillus fumigatus was assessed in an immunosuppressed temporarily leukopenic rabbit model of invasive aspergillosis."	7.68	The role of fluconazole in the early treatment and prophylaxis of experimental invasive aspergillosis. ( Andriole, VT; George, D; Miniter, P; Patterson, TF, 1991)
" Itraconazole was superior to fluconazole in candidosis, cryptococcosis, sporotrichosis and aspergillosis, and to amphotericin B and to flucytosine in candidosis, cryptococcosis and aspergillosis."	7.68	In vitro antifungal spectrum of itraconazole and treatment of systemic mycoses with old and new antimycotic agents. ( Van Cutsem, J, 1992)
" Although the patient was on prophylaxis with fluconazole and she did not respond to amphotericin B, there was an excellent response to itraconazole which allowed the transplant without any Aspergillus infection during both the transplant and the post-transplant periods."	7.68	[Invasive bronchopulmonary aspergillosis treated with itraconazole in a patient with acute leukemia]. ( Alvarez Blanco, A; Alvarez, C; Floristán, F; Hernández, I; Hernández, J; Ponton, J; Sarcía-Ruiz, JC, 1993)
"We report on four cases of aspergillosis which developed during therapy with fluconazole in patients who were immunosuppressed or granulocytopenic."	7.68	Fluconazole in patients at risk from invasive aspergillosis. ( Kappe, R; Osterziel, KJ; Rüchel, R; Siehl, S, 1993)
"Effects on pulmonary cryptococcosis and aspergillosis and the pharmacokinetics of the new antimycotic agent, fluconazole, were examined."	7.67	[The clinical study of fluconazole against pulmonary mycosis. Effects of fluconazole on pulmonary cryptococcosis and aspergillosis, and its pharmacokinetics in patients]. ( Nakashima, M, 1989)
"Disseminated candidiasis is a serious infectious complication with a mortality as high as 50%."	6.68	An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy. ( de Pauw, BE; Donnelly, JP; Kullberg, BJ; Meis, JF; Raemaekers, JM, 1995)
"Fluconazole was confirmed to be an acceptable prophylactic agent early after allogeneic HSCT in appropriately selected patients."	5.48	Antifungal prophylaxis with fluconazole in allogeneic stem cell transplantation recipients who had prior invasive aspergillosis with subsequent complete resolution by computed tomography. ( Akahoshi, Y; Gomyo, A; Harada, N; Hayakawa, J; Ishihara, Y; Kako, S; Kameda, K; Kanda, Y; Kawamura, K; Kikuchi, M; Kimura, SI; Kusuda, M; Nakasone, H; Sakamoto, K; Sato, M; Tamaki, M; Terasako-Saito, K; Ugai, T; Wada, H, 2018)
"To compare the efficacy of caspofungin vs fluconazole prophylaxis against proven or probable invasive fungal disease and invasive aspergillosis during neutropenia following acute myeloid leukemia chemotherapy."	5.30	Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial. ( Alexander, S; Callahan, C; Chen, L; Dang, H; Dvorak, CC; Esbenshade, AJ; Fisher, BT; Nieder, M; Sung, L; Villaluna, D; Wiley, JM; Wingard, JR; Zaoutis, T; Zerr, D, 2019)
"Treatment with fluconazole was effective in this case of semi-invasive aspergillosis."	5.30	[Successful use of fluconazole against semi-invasive--pulmonary aspergillosis]. ( Amemiya, T; Fujimura, M; Kurumaya, H; Matsuda, T; Mizuguchi, M; Nishi, K; Ohka, T; Tachibana, H, 1997)
"Aspergillus infection is the most frequent fungal infection associated with chronic granulomatous disease (CGD), and often results in a life-threatening situation."	5.28	[Effect of fluconazole on Aspergillus infection associated with chronic granulomatous disease]. ( Kawamori, J; Tsuruta, S; Yoshida, T, 1991)
"Fluconazole was found to be effective for the locally invasive form of PA in a healthy man."	5.28	Locally invasive pulmonary aspergillosis in a healthy man successfully treated with oral fluconazole. ( Fujimura, M; Matsuda, T; Myou, S; Nishi, K; Ooka, T, 1992)
"Fluconazole is a novel triazole antifungal agent."	5.28	[A clinical study of fluconazole in pulmonary aspergillosis]. ( Yoneda, R, 1989)
"Fluconazole was 5-20-fold more active than ketoconazole against systemic aspergillosis and against systemic, intracranial and pulmonary cryptococcosis but was less active than amphotericin B."	5.27	Efficacy of fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice. ( Andrews, RJ; Marriott, MS; Richardson, K; Troke, PF, 1987)
"5 mg/kg twice daily; N=248) with fluconazole oral solution or capsules (400 mg daily; N=246) in 494 patients with anticipated profound neutropenia (i."	5.12	An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. ( Andreesen, R; Bertz, H; Bodenstein, H; Boewer, C; Cornely, O; Dölken, G; Glasmacher, A; Hänel, M; Junghanss, C; Pasold, R; Ullmann, AJ; Wandt, H; Wedding, U; Wolf, HH, 2006)
" We performed a randomized trial to compare itraconazole vs fluconazole, for prevention of IFIs in patients with acute leukemia (AL) and HSCT recipients."	5.12	A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. ( Akria, L; Benyamini, N; Dally, N; Dann, EJ; Fineman, R; Gorelik, A; Haddad, N; Oren, I; Rowe, JM; Sprecher, H; Tamir, A; Zuckerman, T, 2006)
"In an international, randomized, double-blind trial, we compared oral posaconazole with oral fluconazole for prophylaxis against invasive fungal infections in patients with graft-versus-host disease (GVHD) who were receiving immunosuppressive therapy."	5.12	Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. ( Boparai, N; Chandrasekar, P; Durrant, S; Greinix, H; Langston, A; Lipton, JH; Morais de Azevedo, W; Patino, H; Pedicone, L; Reddy, V; Tarantolo, SR; Ullmann, AJ; Vesole, DH, 2007)
"Reported sensitivity of the galactomannan enzyme immunoassay as an early diagnostic test for invasive aspergillosis (IA) has been widely variable, ranging from 29% to 100% in earlier clinical studies."	5.11	Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. ( Gugel, A; Laverdiere, M; Leisenring, W; Marr, KA, 2005)
" By day 50, the incidence of Candida infections in the high-dose group was 4% (95% confidence interval [CI]: 1% to 7%; n = 5), compared with 1% in the low-dose fluconazole group (95% CI: 0% to 3%; n = 1; P = 0."	5.10	Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy. ( DeFor, TE; Goodman, JL; MacMillan, ML; Weisdorf, DJ, 2002)
"To compare the benefits and harms of voriconazole with those of amphotericin B and fluconazole when used for prevention or treatment of invasive fungal infections in cancer patients with neutropenia."	4.90	Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia. ( Dalbøge, CS; Gøtzsche, PC; Johansen, HK; Jørgensen, KJ, 2014)
" Terms such as micafungin, aspergillosis, zygomycosis, invasive fungal infections, emerging fungal infections, antifungal treatment or therapy, antifungal prophylaxis, empiric or pre-emptive therapy were crossed."	4.85	[Future role of micafungin in the treatment of invasive mycoses caused by filamentous fungi]. ( Salavert-Lletí, M; Zaragoza-Crespo, R, 2009)
"To compare the benefits and harms of voriconazole with those of amphotericin B and fluconazole when used for prevention or treatment of invasive fungal infections in cancer patients with neutropenia."	4.83	Voriconazole versus amphotericin B in cancer patients with neutropenia. ( Gøtzsche, PC; Johansen, HK; Jørgensen, KJ, 2006)
" Oral candidiasis in immunocompromised patients also requires systemic treatment; oral fluconazole and itraconazole oral solution are highly effective in this setting."	4.81	Current management of fungal infections. ( Meis, JF; Verweij, PE, 2001)
" Fluconazole (Diflucan) is currently the standard prophylactic agent for candidiasis, although mold-active agents and alternative strategies for polyene administration are being investigated."	4.81	Antifungal prophylaxis in hematopoietic stem cell transplant recipients. ( Marr, KA, 2001)
"We reported a case of aspergillosis presented as cholangitis in a patient after liver transplantation, even with prophylactic use of fluconazole."	3.76	Aspergillosis of biliary tract after liver transplantation: a case report. ( Dingheng, Z; Hongyu, Y; Jianghan, C; Jing, H; Yuchong, C; Zhizhong, Y, 2010)
" On day 72 posttransplant, because of invasive aspergillosis, antifungal therapy was switched to intravenous voriconazole 400 mg every 12 hours on the first day, followed by 200 mg every 12 hours; to prevent drug toxicity, the everolimus dosage was promptly lowered to 0."	3.74	Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. ( Adani, GL; Baccarani, U; Baraldo, M; Cojutti, P; Franceschi, L; Furlanut, M; Londero, A; Pea, F; Tavio, M; Viale, P, 2008)
" Four patients presented nausea and vomiting as an AE, although aerosolized amphotericin B was ongoing."	3.74	Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation. ( Borro, JM; de la Torre, M; Delgado, M; Fernandez, R; Gonzalez, D; Monte, E; Pastor, A; Saura, A; Solé, A, 2008)
" The drug is available for intravenous or oral administration and has been shown to be effective in invasive aspergillosis, fluconazole-susceptible and -resistant candidiasis, and infections caused by various other fungal pathogens, including some formerly refractory organisms."	3.73	Voriconazole: a broad spectrum triazole for the treatment of serious and invasive fungal infections. ( Haas, A; Maschmeyer, G, 2006)
"The aim of this investigation was to create a reproducible experimental model of disseminated Aspergillus flavus aspergillosis, and to compare the relative therapeutic efficacies of itraconazole and fluconazole in this model."	3.72	Disseminated aspergillosis due to Aspergillus flavus in an experimental model: efficacy of azole therapy. ( Geraldine, P; Kaliamurthy, J; Thomas, PA, 2003)
"To investigate the therapeutic role of topical and oral fluconazole treatment using a rabbit model of Aspergillus fumigatus keratitis."	3.72	Comparison of efficacy of topical and oral fluconazole treatment in experimental Aspergillus keratitis. ( Avunduk, AM; Beuerman, RW; Greer, D; Kaufman, HE; Warnel, ED, 2003)
" In neutropenic mouse models of disseminated candidiasis and pulmonary aspergillosis, the efficacy of MCFG was superior to that of fluconazole and itroconazole, but comparable to that of amphotericin B."	3.72	[Antifungal activity and clinical efficacy of micafungin sodium (Funguard)]. ( Ikeda, F, 2003)
"Due to an increasing number of leukemic patients with invasive gingival aspergillosis during neutropenia (neutrophils <500 cells/microl for >10 days), we evaluated the efficacy of oral itraconazole prophylaxis for preventing this invasive infection at our hospital."	3.71	Itraconazole prophylaxis for invasive gingival aspergillosis in neutropenic patients with acute leukemia. ( Fujihara, M; Kyo, T; Mikami, Y; Myoken, Y; Sugata, T, 2002)
" One patient had developed a chronic systemic candidiasis during consolidation chemotherapy and received prophylactic oral or iv fluconazole (200 mg daily) throughout BMT."	3.69	Successful bone marrow transplantation in patients with previous invasive fungal infections: report of four cases. ( Altés, A; Brunet, S; Domingo-Albós, A; Martínez, C; Martino, R; Nomdedéu, J; Sureda, A, 1994)
"7 of 8 dogs receiving combination drug therapy consisting of flucytosine together with amphotericin B and/or a triazole for cryptococcosis or aspergillosis developed cutaneous or mucocutaneous eruptions during the course of treatment."	3.69	Suspected drug eruption in seven dogs during administration of flucytosine. ( Love, DN; Malik, R; Medeiros, C; Wigney, DI, 1996)
"We report on four cases of aspergillosis which developed during therapy with fluconazole in patients who were immunosuppressed or granulocytopenic."	3.68	Fluconazole in patients at risk from invasive aspergillosis. ( Kappe, R; Osterziel, KJ; Rüchel, R; Siehl, S, 1993)
"The efficacy of fluconazole against Aspergillus fumigatus was assessed in an immunosuppressed temporarily leukopenic rabbit model of invasive aspergillosis."	3.68	The role of fluconazole in the early treatment and prophylaxis of experimental invasive aspergillosis. ( Andriole, VT; George, D; Miniter, P; Patterson, TF, 1991)
"The triazole Bay R 3783 was compared with fluconazole, itraconazole, ketoconazole, and amphotericin B in rodent models of superficial and systemic candidiasis, meningocerebral cryptococcosis, and pulmonary aspergillosis."	3.68	Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis. ( Hector, RF; Yee, E, 1990)
" Although the patient was on prophylaxis with fluconazole and she did not respond to amphotericin B, there was an excellent response to itraconazole which allowed the transplant without any Aspergillus infection during both the transplant and the post-transplant periods."	3.68	[Invasive bronchopulmonary aspergillosis treated with itraconazole in a patient with acute leukemia]. ( Alvarez Blanco, A; Alvarez, C; Floristán, F; Hernández, I; Hernández, J; Ponton, J; Sarcía-Ruiz, JC, 1993)
"The triazole SCH39304 was compared with amphotericin B and fluconazole for the treatment of pulmonary aspergillosis in corticoid-immunosuppressed mice intranasally challenged with 5 x 10(6) conidia of Aspergillus fumigatus."	3.68	Pulmonary aspergillosis in mice: treatment with a new triazole SCH39304. ( Defaveri, J; Graybill, JR; Rinaldi, MG; Salazar, MH, 1990)
" Itraconazole was superior to fluconazole in candidosis, cryptococcosis, sporotrichosis and aspergillosis, and to amphotericin B and to flucytosine in candidosis, cryptococcosis and aspergillosis."	3.68	In vitro antifungal spectrum of itraconazole and treatment of systemic mycoses with old and new antimycotic agents. ( Van Cutsem, J, 1992)
"Effects on pulmonary cryptococcosis and aspergillosis and the pharmacokinetics of the new antimycotic agent, fluconazole, were examined."	3.67	[The clinical study of fluconazole against pulmonary mycosis. Effects of fluconazole on pulmonary cryptococcosis and aspergillosis, and its pharmacokinetics in patients]. ( Nakashima, M, 1989)
"Fluconazole, a novel triazole antifungal agent, was given orally or intravenously to 10 patients with pulmonary mycosis (7 patients with primary pulmonary cryptococcosis and 3 with pulmonary aspergillosis)."	3.67	[Clinical efficacy of fluconazole in the patient with pulmonary mycosis]. ( Hanawa, T; Hatakenaka, R; Ikeda, S; Katsura, A; Kosaba, S; Lee, Y; Matsubara, Y; Ninomiya, K; Shiota, T; Yagi, K, 1989)
"Combination pairs of 5-fluorocytosine (5-FC) + itraconazole (Itra), 5-FC + fluconazole (Fluc), and amphotericin B (Amph B) + Itra were administered to mice with experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis with a variety of combination ratios."	3.67	Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice. ( Polak, A, 1987)
" In 234 episodes, initial antifungal treatment consisted of amphotericin B [as monotherapy, n = 193; median dosage (range) of amphotericin B deoxycholate 0."	2.73	Antifungal usage in children undergoing intensive treatment for acute myeloid leukemia: analysis of the multicenter clinical trial AML-BFM 93. ( Creutzig, U; Groll, AH; Kaiser, J; Klingebiel, T; Lehrnbecher, T; Ritter, J; Schwabe, D; Varwig, D, 2007)
"Fluconazole was given 100-200 mg daily for 3 days to 8 months."	2.68	[A multiple center clinical trial on fluconazole for deep-seated fungal infections]. ( Liang, D; Xu, N; Zhang, H, 1995)
"Fungal infections are a major problem in patients with hematologic malignancy."	2.68	Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. ( Schaffner, A; Schaffner, M, 1995)
"Disseminated candidiasis is a serious infectious complication with a mortality as high as 50%."	2.68	An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy. ( de Pauw, BE; Donnelly, JP; Kullberg, BJ; Meis, JF; Raemaekers, JM, 1995)
"Fluconazole (FLCZ) is an antifungal agent of triazole class and has been proven to be effective against deep-seated mycosis caused by Candida spp."	2.67	[Experience of fluconazole granules and injection in pediatric patients]. ( Azuma, E; Ido, M; Ihara, T; Ito, M; Kamiya, H; Nakano, T; Sakurai, M; Yasuda, N, 1994)
"Fluconazole treatment was successful in 53% of the patients."	2.67	Efficacy of fluconazole in the treatment of systemic fungal infections. ( Milatovic, D; Voss, A, 1992)
"Fluconazole is a novel antifungal agent, available in oral and intravenous forms, which was developed by Pfizer Central Research."	2.66	[Clinical study of fluconazole on deep-seated fungal infections]. ( Akahonai, Y; Ikemoto, H; Kasai, M; Kawamura, K; Mikuni, C; Mori, T; Taniuchi, A; Watanabe, K; Yoshida, K; Yoshida, T, 1989)
"Fluconazole was replaced in both twins by liposomal amphotericin B and the incubators were changed."	2.55	Simultaneous primary invasive cutaneous aspergillosis in two preterm twins: case report and review of the literature. ( Astruc, D; Candolfi, E; Denis, J; Dillenseger, L; Gallais, F; Herbrecht, R; Koobar, O; Letscher-Bru, V; Sabou, M, 2017)
"Fungemia is a serious problem within neonatal intensive care units around the world."	2.50	Fungal prophylaxis in neonates: a review article. ( Bradshaw, WT; Lollis, TR, 2014)
"Voriconazole is a second-generation triazole antifungal agent, structurally derived from fluconazole with an extended spectrum of activity against a wide variety of yeasts and moulds."	2.43	Voriconazole: review of a broad spectrum triazole antifungal agent. ( Kofla, G; Ruhnke, M, 2005)
"Opportunistic mycoses have emerged as important causes for morbidity and mortality in pediatric cancer patients, particularly in those with intensively treated hematological malignancies, allogeneic hematopoetic stem cell transplantation, and aplastic anemia."	2.41	[Prevention of fungal infections in children and adolescents with cancer]. ( Groll, AH; Müller, FM; Ritter, J, 2001)
"Amphotericin B has a broad spectrum and has remained the drug of choice for these life threatening invasive fungal infections."	2.41	[Choice and use of antifungal drugs]. ( Dupont, B, 2001)
"However, Candida infections are predominantly caused by colonizing fungi; therefore drug prophylaxis is more promising."	2.40	Prophylaxis of fungal infections. ( Haag, C; Schuler, US, 1997)
" However, bioavailability of itraconazole is reduced in patients with raised gastric pH and no i."	2.39	[Prophylaxis against mycoses in neutropenic patients]. ( Arning, M; Aul, C, 1994)
"Strategies for treating invasive Candida infections must consider the relative rates of non-C."	2.39	Resistance to antifungal agents in the critical care setting: problems and perspectives. ( Martins, MD; Rex, JH, 1996)
"Invasive fungal infections are common in immunocompromised patients."	2.38	[Systemic mycotic infections]. ( Meunier, F, 1990)
"Fluconazole was confirmed to be an acceptable prophylactic agent early after allogeneic HSCT in appropriately selected patients."	1.48	Antifungal prophylaxis with fluconazole in allogeneic stem cell transplantation recipients who had prior invasive aspergillosis with subsequent complete resolution by computed tomography. ( Akahoshi, Y; Gomyo, A; Harada, N; Hayakawa, J; Ishihara, Y; Kako, S; Kameda, K; Kanda, Y; Kawamura, K; Kikuchi, M; Kimura, SI; Kusuda, M; Nakasone, H; Sakamoto, K; Sato, M; Tamaki, M; Terasako-Saito, K; Ugai, T; Wada, H, 2018)
"Of a total of 17 (8."	1.43	Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high-risk liver transplantation recipients: A propensity score analysis. ( Aguado, JM; Bodro, M; Carratalá, J; Casafont, F; Cervera, C; Fariñas, C; Fortún, J; Fresco, G; Gavaldá, J; Goikoetxea, J; Len, O; Martín-Dávila, P; Montejo, M; Moreno, A; Muñoz, P; Muriel, A; Pozo, JC; Silva, JT; Torre-Cisneros, J; Vena, A, 2016)
"Treatment with voriconazole was promptly started with success."	1.43	Acute isolated appendicitis due to Aspergillus carneus in a neutropenic child with acute myeloid leukemia. ( Bergami, E; Cavanna, C; Decembrino, N; Introzzi, F; Lallitto, F; Mangione, F; Marone, P; Tamarozzi, F; Tortorano, AM; Zecca, M, 2016)
"Pulmonary aspergillosis was the most common causative agent, and no patients showed candidemia, or hepatosplenic candidiasis."	1.37	Invasive fungal infections in pediatric patients with hematologic malignancies receiving oral amphotericin B solution and early intravenous administration of fluconazole. ( Kato, K; Kojima, S; Matsumoto, K; Watanabe, N, 2011)
"Fluconazole was given to 17 paitents, intraconazole was given to 21 patients, and intraconazole to the other 9 patients after they had no effect with fluconazole."	1.35	[Clinical features and treatment of invasive fungal infection in 47 patients with hematological malignancies]. ( Chen, SP; Shu, YG; Xu, YJ; Zhu, Y, 2008)
"Thymol was an especially potent chemosensitizing agent for amphotericin B, fluconazole or ketoconazole."	1.35	Chemosensitization prevents tolerance of Aspergillus fumigatus to antimycotic drugs. ( Campbell, B; Chan, K; Kim, J; Mahoney, N; May, G; Molyneux, R, 2008)
"Fluconazole was given as anti-Candida prophylaxis."	1.34	Presumptive treatment strategy for aspergillosis in allogeneic haematopoietic stem cell transplant recipients. ( Arai, S; Asai, T; Asano-Mori, Y; Chiba, S; Hangaishi, A; Hosoya, N; Izutsu, K; Kanda, Y; Kurokawa, M; Motokura, T; Nagai, S; Nishimoto, N; Oshima, K; Sato, H; Watanabe, T, 2007)
"We report a 33-year-old woman with systemic lupus erythematosus undergoing immunotherapy infected with combined invasive pulmonary aspergillosis and pulmonary cryptococcosis diagnosed by video-assisted thoracic surgery lung biopsy and she was successfully treated as a result of early diagnosis and treatment."	1.33	Invasive pulmonary aspergillosis and pulmonary cryptococcosis really coexist in immunocompromised host. ( Chiang, PC; Huang, CC; Huang, SF; Lee, CH; Lin, CM; Liu, HP; Tsai, YH, 2006)
"Posaconazole was active against isolates of Candida and Aspergillus spp."	1.33	In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. ( Black, TA; Hare, R; Loebenberg, D; Mann, PA; McNicholas, PM; Mendrick, CA; Norris, CC; Patel, R; Sabatelli, F, 2006)
"A 19-year-old female with aplastic anemia who developed subglottal aspergillosis is reported."	1.31	Invasive subglottal aspergillosis in a patient with severe aplastic anemia: a case report. ( Itoh, S; Kajiwara, M; Kumagai, J; Nagasawa, M; Sugimoto, T; Tomizawa, D, 2002)
"Fluconazole was labelled with (99m)Tc and radiochemical analysis showed less than 5% impurities."	1.31	Technetium-99m labelled fluconazole and antimicrobial peptides for imaging of Candida albicans and Aspergillus fumigatus infections. ( Lupetti, A; Mazzi, U; Nibbering, PH; Pauwels, EK; Welling, MM, 2002)
"Treatment with fluconazole was effective in this case of semi-invasive aspergillosis."	1.30	[Successful use of fluconazole against semi-invasive--pulmonary aspergillosis]. ( Amemiya, T; Fujimura, M; Kurumaya, H; Matsuda, T; Mizuguchi, M; Nishi, K; Ohka, T; Tachibana, H, 1997)
"Amphotericin B (AMPH) was injected daily in 5 patients, Fulconazol (FCZ) in 2 patients, and both in the remaining patient."	1.29	[Percutaneous intracavitary treatment of pulmonary aspergilloma-clinical efficacy and prognosis]. ( Furuse, F; Hara, N; Ikeda, T; Inoue, H; Kotoh, H; Nakanishi, Y; Yatsunami, J, 1994)
"Treatment with fluconazole, amphotericin B, or a combination of both significantly prolonged survival of animals lethally challenged with Aspergillus fumigatus."	1.29	Combination therapy in experimental invasive aspergillosis. ( Andriole, VT; George, D; Kordick, D; Miniter, P; Patterson, TF, 1993)
"Aspergillus endocarditis has been considered as a fatal disease because of the difficulty of diagnosis and treatment."	1.29	[Two cases of Aspergillus endocarditis after cardiac surgery in childhood]. ( Kawasaki, S; Komai, Y; Naitoh, Y; Noguchi, Y; Takagaki, Y, 1996)
" When combined with amphotericin B (AmB), however, DU-6859a clearly enhanced the in vitro antifungal activity of AmB against Candida albicans, Candida tropicalis, Candida krusei, Candida glabrata, and Cryptococcus neoformans in microdilution checkerboard studies."	1.29	In vitro and in vivo antifungal activities of DU-6859a, a fluoroquinolone, in combination with amphotericin B and fluconazole against pathogenic fungi. ( Kitamura, A; Nakajima, R; Sato, K; Someya, K; Tanaka, M, 1995)
"Fluconazole was superior to oral amphotericin B in the treatment of C."	1.28	Surveillance and treatment of liver transplant recipients for candidiasis and aspergillosis. ( Bordone, G; Colledan, M; Malaspina, C; Pagano, A; Paone, G; Rossi, G; Tortorano, AM; Viviani, MA, 1992)
"Fluconazole was found to be effective for the locally invasive form of PA in a healthy man."	1.28	Locally invasive pulmonary aspergillosis in a healthy man successfully treated with oral fluconazole. ( Fujimura, M; Matsuda, T; Myou, S; Nishi, K; Ooka, T, 1992)
"Aspergillus infection is the most frequent fungal infection associated with chronic granulomatous disease (CGD), and often results in a life-threatening situation."	1.28	[Effect of fluconazole on Aspergillus infection associated with chronic granulomatous disease]. ( Kawamori, J; Tsuruta, S; Yoshida, T, 1991)
"In its early stage, cranial nerve palsies are caused by nerve compression or invasion by this disease."	1.28	[Sphenoid sinus aspergillosis presenting abducens nerve palsy and visual field impairment; a case report]. ( Basugi, N; Eguchi, M; Matsuno, A; Yoshida, S, 1992)
"Fluconazole was markedly effective against septicemia due to Candida and oral candidiasis accompanied with lingual ulcer in spite of seriousness of these underlying disease."	1.28	[Clinical evaluation of fluconazole in patients with mycotic infection]. ( Adachi, M; Ikeda, H; Kawanishi, M; Matsushima, T; Nakamura, J; Tanabe, J; Tano, Y; Tomizawa, S, 1989)
"Fluconazole was about four times less effective than SM-8668 against systemic candidiasis and was only slightly effective at doses of 80 and 25 mg/kg against systemic aspergilosis and cryptococcosis, respectively."	1.28	In vivo efficacy of SM-8668 (Sch 39304), a new oral triazole antifungal agent. ( Ichise, K; Nakajima, T; Okuda, T; Tanio, T, 1990)
"Fluconazole was administered orally at a daily dose of 100 mg and 200 mg, respectively (n = 29), or intravenously at a dose of 100 mg and 400 mg (n = 2)."	1.28	[Prophylaxis and therapy of fungal infections with fluconazole in patients after bone marrow transplantation]. ( Beelen, DW; Dermoumi, H; Kölbel, M; Kraft, J; Müller, KD; Quabeck, K; Schaefer, UW, 1990)
"Fluconazole is a novel triazole antifungal agent."	1.28	[A clinical study of fluconazole in pulmonary aspergillosis]. ( Yoneda, R, 1989)
"Fluconazole was 5-20-fold more active than ketoconazole against systemic aspergillosis and against systemic, intracranial and pulmonary cryptococcosis but was less active than amphotericin B."	1.27	Efficacy of fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice. ( Andrews, RJ; Marriott, MS; Richardson, K; Troke, PF, 1987)

Research

Studies (194)

Authors

Clinical Trials (11)

Trial Overview

Trial Outcomes

Overall Survival

Timeframe	Studies, this research(%)	All Research%
pre-1990	7 (3.61)	18.7374
1990's	81 (41.75)	18.2507
2000's	78 (40.21)	29.6817
2010's	26 (13.40)	24.3611
2020's	2 (1.03)	2.80

Authors	Studies
Bartroli, J	2
Turmo, E	2
Algueró, M	2
Boncompte, E	2
Vericat, ML	2
Conte, L	2
Ramis, J	2
Merlos, M	2
García-Rafanell, J	2
Forn, J	2
Meulbroek, JA	1
Nilius, AM	1
Li, Q	1
Wang, W	1
Hasvold, L	1
Steiner, B	1
Dickman, DA	1
Ding, H	1
Frost, D	1
Goldman, RC	1
Lartey, P	1
Plattner, JJ	1
Bennani, YL	1
Fritsche, TR	1
Rhomberg, PR	1
Sader, HS	1
Jones, RN	1
Mitsuyama, J	1
Nomura, N	1
Hashimoto, K	1
Yamada, E	1
Nishikawa, H	1
Kaeriyama, M	1
Kimura, A	1
Todo, Y	1
Narita, H	2
Arendrup, MC	1
Garcia-Effron, G	1
Buzina, W	2
Mortensen, KL	1
Reiter, N	2
Lundin, C	1
Jensen, HE	1
Lass-Flörl, C	2
Perlin, DS	1
Bruun, B	1
Yates, CM	1
Garvey, EP	1
Shaver, SR	1
Schotzinger, RJ	1
Hoekstra, WJ	1
Erami, M	1
Hashemi, SJ	2
Raiesi, O	1
Fattahi, M	1
Getso, MI	1
Momen-Heravi, M	1
Daie Ghazvini, R	2
Khodavaisy, S	1
Parviz, S	1
Mehri, N	1
Babaei, M	1
Fisher, BT	1
Zaoutis, T	1
Dvorak, CC	1
Nieder, M	1
Zerr, D	1
Wingard, JR	2
Callahan, C	1
Villaluna, D	1
Chen, L	1
Dang, H	1
Esbenshade, AJ	1
Alexander, S	1
Wiley, JM	1
Sung, L	1
Meryk, A	1
Kropshofer, G	1
Hutter, J	1
Fritz, J	1
Salvador, C	1
Crazzolara, R	1
Gallais, F	1
Denis, J	1
Koobar, O	1
Dillenseger, L	1
Astruc, D	1
Herbrecht, R	1
Candolfi, E	1
Letscher-Bru, V	1
Sabou, M	1
Akahoshi, Y	1
Kimura, SI	1
Gomyo, A	1
Hayakawa, J	1
Tamaki, M	1
Harada, N	1
Kusuda, M	1
Kameda, K	1
Ugai, T	1
Wada, H	2
Ishihara, Y	1
Kawamura, K	2
Sakamoto, K	1
Sato, M	1
Terasako-Saito, K	1
Kikuchi, M	1
Nakasone, H	1
Kako, S	1
Kanda, Y	3
Kamali Sarwestani, Z	1
Rezaie, S	1
Gerami Shoar, M	1
Mahmoudi, S	1
Elahi, M	1
Bahardoost, M	1
Tajdini, A	1
Abutalebian, S	1
Lee, Y	2
Lee, KT	1
Lee, SJ	1
Beom, JY	1
Hwangbo, A	1
Jung, JA	1
Song, MC	1
Yoo, YJ	1
Kang, SH	1
Averette, AF	1
Heitman, J	1
Yoon, YJ	1
Cheong, E	1
Bahn, YS	1
Barrs, VR	1
van Doorn, TM	1
Houbraken, J	1
Kidd, SE	1
Martin, P	1
Pinheiro, MD	1
Richardson, M	1
Varga, J	1
Samson, RA	1
van der Elst, KC	1
Span, LF	1
van Hateren, K	1
Vermeulen, KM	1
van der Werf, TS	1
Greijdanus, B	1
Kosterink, JG	1
Uges, DR	1
Alffenaar, JW	1
Maly, J	1
Szarszoi, O	1
Netuka, I	1
Dorazilova, Z	1
Pirk, J	1
Lollis, TR	1
Bradshaw, WT	1
Jørgensen, KJ	2
Gøtzsche, PC	2
Dalbøge, CS	1
Johansen, HK	2
Valerio, M	1
Vena, A	2
Bouza, E	2
Viale, P	2
Hochreiter, M	1
Giannella, M	1
Muñoz, P	2
Veraldi, S	1
Grancini, A	1
Venegoni, L	1
Merlo, V	1
Guanziroli, E	1
Menicanit, C	1
Nazzaro, G	1
Tortorano, A	1
Fortún, J	1
Muriel, A	1
Martín-Dávila, P	1
Montejo, M	1
Len, O	1
Torre-Cisneros, J	1
Carratalá, J	1
Fariñas, C	1
Moreno, A	1
Fresco, G	1
Goikoetxea, J	1
Gavaldá, J	1
Pozo, JC	1
Bodro, M	1
Casafont, F	1
Cervera, C	1
Silva, JT	1
Aguado, JM	1
Decembrino, N	1
Zecca, M	1
Tortorano, AM	2
Mangione, F	1
Lallitto, F	1
Introzzi, F	1
Bergami, E	1
Marone, P	1
Tamarozzi, F	1
Cavanna, C	1
Karthaus, M	2
Pea, F	1
Baccarani, U	1
Tavio, M	1
Cojutti, P	1
Adani, GL	1
Londero, A	1
Baraldo, M	1
Franceschi, L	1
Furlanut, M	1
Rutt, AL	1
Sataloff, RT	2
Borro, JM	1
Solé, A	1
de la Torre, M	1
Pastor, A	1
Fernandez, R	1
Saura, A	1
Delgado, M	1
Monte, E	1
Gonzalez, D	1
Salavert-Lletí, M	1
Zaragoza-Crespo, R	1
Yuchong, C	1
Dingheng, Z	1
Zhizhong, Y	1
Hongyu, Y	1
Jing, H	1
Jianghan, C	1
Lupetti, A	2
de Boer, MG	1
Erba, P	1
Campa, M	1
Nibbering, PH	2
Carter, SL	1
Walsh, TJ	3
Kurtzberg, J	1
Small, TN	1
Baden, LR	1
Gersten, ID	1
Mendizabal, AM	1
Leather, HL	1
Confer, DL	1
Maziarz, RT	1
Stadtmauer, EA	1
Bolaños-Meade, J	1
Brown, J	1
Dipersio, JF	1
Boeckh, M	2
Marr, KA	4
Phute, SU	1
Bhakre, JB	1
Khan, MS	1
Ahmad, I	1
Watanabe, N	1
Matsumoto, K	1
Kojima, S	1
Kato, K	1
Ramírez, E	1
García-Rodríguez, J	1
Borobia, AM	1
Ortega, JM	1
Lei, S	1
Barrios-Fernández, A	1
Sánchez, M	1
Carcas, AJ	1
Herrero, A	1
de la Puente, JM	1
Frías, J	1
Blosser, SJ	1
Cramer, RA	1
Selvakumar, P	1
Sofia, O	1
Gopal, L	1
Biswas, J	1
Walker, JT	1
Frazho, JK	1
Randell, SC	1
Goodman, D	1
Pamer, E	1
Jakubowski, A	1
Morris, C	1
Sepkowitz, K	1
Biancofiore, G	1
Bindi, ML	1
Baldassarri, R	1
Romanelli, AM	1
Catalano, G	1
Filipponi, F	1
Vagelli, A	1
Mosca, F	1
Oliveira, JS	1
Kerbauy, FR	1
Colombo, AL	1
Bahia, DM	1
Pinheiro, GS	1
Silva, MR	1
Ribeiro, MS	1
Raineri, G	1
Kerbauy, J	1
Singh, N	1
Koh, LP	1
Kurup, A	1
Goh, YT	1
Fook-Chong, SM	1
Tan, PH	1
Miyabe, S	1
Koizuka, I	1
Ochi, K	1
Tanaka, K	1
Kuroda, H	1
Kenmochi, M	1
Okada, T	1
Tomisawa, H	1
Sugiyama, Y	1
Avunduk, AM	2
Beuerman, RW	2
Varnell, ED	1
Kaufman, HE	2
Sandhu, S	1
Kaur, T	1
Yasokawa, YT	1
Yano, H	1
Murase, S	1
Shinoda, J	1
Sakai, N	1
Oshima, K	2
Iino, N	1
Sasaki, N	1
Takahashi, N	1
Tanabe, Y	1
Ito, S	1
Ueno, M	1
Nishi, S	1
Tsukada, H	1
Narita, I	1
Hasegawa, G	1
Suzuki, E	1
Gejyo, F	1
Kaliamurthy, J	1
Geraldine, P	1
Thomas, PA	1
Warnel, ED	1
Greer, D	1
Zielińska, E	1
Ikeda, F	1
Tsuchiyama, T	1
Naitoh, H	1
Kouzuma, K	1
Motoyama, H	1
Kinuwaki, E	1
Crippa, F	1
Leisenring, W	2
Hoyle, M	1
Balajee, SA	1
Nichols, WG	1
Musher, B	1
Corey, L	1
Garg, P	1
Mahesh, S	1
Bansal, AK	1
Gopinathan, U	1
Rao, GN	1
Kohno, S	2
Park, SB	1
Kang, MJ	1
Whang, EA	1
Han, SY	1
Kim, HC	1
Park, KK	1
Yoshida, M	2
Marr, K	1
Lin, CP	1
Chang, CW	1
Su, CY	1
O'Neill, JT	1
Blair, M	1
Graham, BS	1
Laverdiere, M	1
Gugel, A	1
Kofla, G	1
Ruhnke, M	1
Cowen, LE	1
Lindquist, S	1
Lin, CM	1
Tsai, YH	1
Huang, CC	1
Lee, CH	1
Chiang, PC	1
Huang, SF	1
Liu, HP	1
Manzoni, P	1
Arisio, R	1
Mostert, M	1
Leonessa, M	1
Farina, D	1
Latino, MA	1
Gomirato, G	1
Glasmacher, A	2
Cornely, O	1
Ullmann, AJ	2
Wedding, U	1
Bodenstein, H	1
Wandt, H	1
Boewer, C	1
Pasold, R	1
Wolf, HH	1
Hänel, M	1
Dölken, G	1
Junghanss, C	1
Andreesen, R	1
Bertz, H	1
Shen, Q	1
Song, XM	1
Xu, XP	1
Wang, JM	1
Halliday, C	1
Hoile, R	1
Sorrell, T	1
James, G	1
Yadav, S	1
Shaw, P	1
Bleakley, M	1
Bradstock, K	1
Chen, S	1
Marik, PE	1
Rogers, TR	1
Sabatelli, F	1
Patel, R	1
Mann, PA	1
Mendrick, CA	1
Norris, CC	1
Hare, R	1
Loebenberg, D	2
Black, TA	1
McNicholas, PM	1
Sahin, GO	1
Akova, M	1
Oren, I	1
Rowe, JM	1
Sprecher, H	1
Tamir, A	1
Benyamini, N	1
Akria, L	1
Gorelik, A	1
Dally, N	1
Zuckerman, T	1
Haddad, N	1
Fineman, R	1
Dann, EJ	1
Rodrigo, N	1
Perera, KN	1
Ranwala, R	1
Jayasinghe, S	1
Warnakulasuriya, A	1
Hapuarachchi, S	1
Lipton, JH	1
Vesole, DH	1
Chandrasekar, P	1
Langston, A	1
Tarantolo, SR	1
Greinix, H	1
Morais de Azevedo, W	1
Reddy, V	1
Boparai, N	1
Pedicone, L	1
Patino, H	1
Durrant, S	1
De Pauw, BE	4
Donnelly, JP	3
Kauffman, CA	2
Malani, AN	1
Easley, C	1
Kirkpatrick, P	1
Asano-Mori, Y	1
Nishimoto, N	1
Arai, S	1
Nagai, S	1
Sato, H	1
Watanabe, T	1
Hosoya, N	1
Izutsu, K	1
Asai, T	1
Hangaishi, A	1
Motokura, T	1
Chiba, S	1
Kurokawa, M	1
Maschmeyer, G	1
Haas, A	1
Lehrnbecher, T	1
Kaiser, J	1
Varwig, D	1
Ritter, J	2
Groll, AH	2
Creutzig, U	1
Klingebiel, T	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)[NCT01307579]	Phase 3	517 participants (Actual)	Interventional	2011-04-04	Completed
A Randomized Double-blind Trial of Fluconazole Versus Voriconazole for the Prevention of Invasive Fungal Infections in Allogeneic Blood and Marrow Transplant Patients (BMT CTN #0101)[NCT00075803]	Phase 3	600 participants (Actual)	Interventional	2003-11-30	Completed
Collection of Granulocytes by Apheresis of Healthy Donors Stimulated With Filgrastim (G-CSF) and Dexamethasone[NCT01553214]	Phase 4	1,000 participants (Anticipated)	Interventional	2012-12-31	Recruiting
Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation[NCT01160952]	Phase 2	120 participants (Anticipated)	Interventional	2009-05-31	Recruiting
ANTIVORIFUNGOL:Strategy of Antifungal Use in Oncohematological Neutropenic Patients. Use of Voriconazole as Early Treatment.[NCT00386802]	Phase 4	115 participants (Anticipated)	Interventional	2006-08-31	Completed
[NCT00034645]	Phase 3	600 participants (Actual)	Interventional	1999-01-31	Completed
Invasive Fungal Infections in Patients Following Stem Cell Transplant[NCT04619147]		300 participants (Anticipated)	Observational	2021-01-31	Not yet recruiting
An Open Intravenous Multiple Dose, Multi-Center Study to Investigate the Pharmacokinetics, Safety and Toleration of Voriconazole in Children Aged 2-12 Years Who Require Treatment for the Prevention of Systemic Fungal Infection[NCT00005912]	Phase 1	48 participants	Interventional	2000-06-30	Completed
A Phase II Trial to Evaluate the Safety and Tolerability of Nebulised Amphotericin B Lipid Complex (ABELCET®) in the Prophylaxis of Invasive Pulmonary Aspergillosis During Prolonged Neutropenia in Paediatric Patients With Acute Leukaemia[NCT01615809]	Phase 2	32 participants (Actual)	Interventional	2011-10-31	Completed
Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia[NCT00001790]	Phase 1	120 participants	Interventional	1998-10-31	Completed
PROCAS: Study Observational Prospective and Multicenter to Determine the Clinic Effectiveness and the Safety of Caspofungin Acetate (CANCIDAS®) in the Treatment of Invader Fungal Infection[NCT00388167]		320 participants (Anticipated)	Observational	2004-03-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Kaplan Meier method will be used to estimate overall survival. Time to event is from enrollment to date of death (by any cause). Participants are censored at last contact or 2 years anniversary of enrollment into this study, whichever occurred first. (NCT01307579)
Timeframe: Up to 2 years post enrollment

Percentage of Participants That Need Empiric Antifungal Therapy

Intervention	Percentage of participants (Number)
Arm I (Caspofungin Acetate)	68.8
Arm II (Fluconazole)	70.8

The percentage of participants requiring empiric antifungal therapy will be determined based on the presence of prolonged fever and neutropenia during each neutropenia course. (NCT01307579)
Timeframe: Up to 5 months since enrollment

Percentage of Participants With Proven or Probable Invasive Aspergillosis (IA)

Intervention	Percentage of participants (Number)
Arm I (Caspofungin Acetate)	71.9
Arm II (Fluconazole)	69.5

Proven or probable invasive aspergillosis (IA) is defined according to the criteria developed by the EORTC/MSG. Kaplan Meier approach will used to estimate the incidence. (NCT01307579)
Timeframe: Up to 5 months since enrollment

Percentage of Participants With Proven or Probable Invasive Fungal Infections (IFI)

Intervention	Percentage of participants (Number)
Arm I (Caspofungin Acetate)	0.5
Arm II (Fluconazole)	3.1

Proven or probable IFI is defined according to criteria developed by the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG). (NCT01307579)
Timeframe: Up to 5 months since enrollment

Failure to Engraft

Frequency of Invasive Fungal Infections (IFI)

Intervention	Percentage of participants (Number)
Arm I (Caspofungin Acetate)	3.1
Arm II (Fluconazole)	7.2

Intervention	participants (Number)
Fluconazole	11
Voriconazole	9

Incidence of proven, probably, or presumptive IFI (NCT00075803)
Timeframe: 1 year

Frequency of Use of Amphotericin B or Caspofungin

Fungal-free Survival (Percentage of Participants Alive and Free From Proven, Probable, or Presumptive Invasive Fungal Infection) at 180 Days Post-transplant

Duration of Use of Amphotericin B or Caspofungin

Freedom From Possible, Presumptive, Probable, or Proven Invasive Fungal Infection, Death, or Withdrawal of Study Drug Due to Toxicity, Intolerance, or an Empirical Trial of Amphotericin B or Caspofungin Greater Than 14 Consecutive Days

Overall Survival

Percentage of Patients With Invasive Fungal Infection at 100, 180, and 365 Days

Relapse Free Survival

Time to and Severity of Acute and Chronic Graft vs Host Disease (GVHD)

Utility of Galactomannan Assay in Diagnosis of Aspergillus and Response to Therapy

Intervention	percentage of patients (Number)
Fluconazole	13.7
Voriconazole	12.7

Intervention	percentage of patients (Number)
Fluconazole	30.2
Voriconazole	24.1

Intervention	percentage of patients (Number)
Fluconazole	74.9
Voriconazole	78.2

Intervention	days (Mean)
	Number of days on study drug	Start day of empiric antifungal therapy	Days of empiric antifungal therapy
Fluconazole	91	16	7
Voriconazole	96	12	7

Intervention	participants (Number)
	IFI after relapse/progression	IFI before engraftment	IFI who had failure to engraft	IFI after aGVHD (grades II-IV)	IFI while on study drug (up to day 100)	IFI after premature withdrawal of study drug	IFI after start other prophylaxis (not study drug)	IFI after empiric therapy
Fluconazole	2	12	2	11	19	11	8	13
Voriconazole	8	8	1	14	10	16	11	12

Intervention	percentage of patients (Number)
	100 days	180 days	365 days
Fluconazole	85.4	80.0	70.2
Voriconazole	90.1	81.2	67.8

Intervention	percentage of patients (Number)
	100 days	180 days	365 days
Fluconazole	9.5	11.2	13.7
Voriconazole	5.6	7.3	12.7

Intervention	percentage of patients (Number)
	100 days	180 days	365 days
Fluconazole	83.1	74.9	63.3
Voriconazole	86.1	73.9	61.2

Intervention	participants (Number)
	Acute GVHD grade II-IV at day 100	Acute GVHD grade III-IV at day 100	Chronic GVHD at 1 year
Fluconazole	132	42	138
Voriconazole	116	27	137

Although there were 82 Galactomannan (GM) positives, 4 were excluded due to piperacillin/tazobactam administration, without other documentation of IFI, and were deemed false positives. (NCT00075803)
Timeframe: 1 year

Efficacy of Primary Prophylaxis With Nebulized Abelcet® on the Incidence of Invasive Pulmonary Aspergillosis

Intervention	participants (Number)
	GM+	GM-
Fluconazole	43	252
Voriconazole	35	270

The incidence of invasive pulmonary aspergillosis during the Abelcet® prophylactic treatment period was assessed by the relation between the number of patients with invasive pulmonary aspergillosis and the number of paediatric patients on prophylaxis with Acute Leukaemia (AL) undergoing intensive chemotherapy. (NCT01615809)
Timeframe: at the Baseline visit (week 1) and at the end of the profilaxis treatment phase, up to 6 weeks

Invasive Pulmonary Aspergillosis -Related Mortality During Primary Prophylaxis With Abelcet®.

Intervention	participants (Number)
Amphotericin B (ABELCET®)	3

Percentage of deaths related to Invasive Pulmonary Aspergillosis during the prophylactic treatment period with Abelcet® in paediatric patients with Acute Leukaemia undergoing intensive chemotherapy. (NCT01615809)
Timeframe: at the Baseline visit (week 1) and at the end of the profilaxis treatment phase, up to 6 weeks

Number of Participants With Adverse Events That Results in the Interruption of Treatment, as a Measure of Safety and Tolerability

Intervention	percentage of deaths (Number)
Amphotericin B (ABELCET®)	0

is assessed by the proportion of patients who discontinue prophylactic treatment with Abelcet® due to an adverse event that is related or not to the study drug or for intolerability to it. The last week of treatment will have a different calendar for each participant, depending on the number of cicles needed by each patient (it has been anticipated up to 5 cicles of 2-6 weeks each). (NCT01615809)
Timeframe: at the Baseline visit (week 1) and during the Last week of treatment, up to 6 weeks

Article	Year
Simultaneous primary invasive cutaneous aspergillosis in two preterm twins: case report and review of the literature. BMC infectious diseases, 2017, 08-02, Volume: 17, Issue:1 Topics: Adult; Amphotericin B; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Diseases in Twins; F	2017
Fungal infections associated with long-term mechanical circulatory support-diagnosis and management. Journal of cardiac surgery, 2014, Volume: 29, Issue:1 Topics: Antifungal Agents; Aspergillosis; Candidiasis; Fluconazole; Heart Failure; Heart-Assist Devices; Hum	2014
Fungal prophylaxis in neonates: a review article. Advances in neonatal care : official journal of the National Association of Neonatal Nurses, 2014, Volume: 14, Issue:1 Topics: Administration, Intravenous; Administration, Oral; Amphotericin B; Antifungal Agents; Aspergillosis;	2014
Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia. The Cochrane database of systematic reviews, 2014, Feb-24, Issue:2 Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Fluconazole; Humans; Liposomes; Mycoses; Neoplasms	2014
[Future role of micafungin in the treatment of invasive mycoses caused by filamentous fungi]. Revista iberoamericana de micologia, 2009, Mar-31, Volume: 26, Issue:1 Topics: Adult; Animals; Antifungal Agents; Aspergillosis; Candidiasis; Child; Clinical Trials as Topic; Doub	2009
Radiotracers for fungal infection imaging. Medical mycology, 2011, Volume: 49 Suppl 1 Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Candida albicans; Candidiasis; Chi	2011
Aspergillus--classification and antifungal susceptibilities. Current pharmaceutical design, 2013, Volume: 19, Issue:20 Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillus; Drug Resistance, Fungal; Fluconazole; Flucyt	2013
The changing face of invasive aspergillosis in liver transplant recipients. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2002, Volume: 8, Issue:11 Topics: Antifungal Agents; Aspergillosis; Fluconazole; Humans; Kidney; Liver; Liver Transplantation; Opportu	2002
[Controversy concerning optimal prophylaxis and empirical antifungal therapy in immunocompromised patients]. Przeglad epidemiologiczny, 2003, Volume: 57, Issue:2 Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Candidiasis; Drug Administration Schedule; Flucona	2003
[Guidelines for the management of deep mycosis in neutropenic patients]. Nihon Ishinkin Gakkai zasshi = Japanese journal of medical mycology, 2004, Volume: 45, Issue:4 Topics: Amphotericin B; Aspergillosis; Candidiasis; Echinocandins; Fluconazole; Humans; Lipopeptides; Lipopr	2004
Combination antifungal therapy: where are we now, and where are we going? Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:13 Suppl 7 Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Azoles; Candidiasis; Caspofungin; Disease	2004
Voriconazole: review of a broad spectrum triazole antifungal agent. Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:7 Topics: Administration, Oral; Animals; Antifungal Agents; Aspergillosis; Candidiasis; Caspofungin; Cryptococ	2005
Voriconazole versus amphotericin B in cancer patients with neutropenia. The Cochrane database of systematic reviews, 2006, Jan-25, Issue:1 Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Fluconazole; Humans; Liposomes; Mycoses; Neoplasms	2006
Fungal infections in solid organ transplantation. Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:3 Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Candidiasis; Caspofungin; Clinical Trials as Topic	2006
Antifungal drug resistance: limited data, dramatic impact? International journal of antimicrobial agents, 2006, Volume: 27 Suppl 1 Topics: Antifungal Agents; Aspergillosis; Candidiasis; Drug Resistance, Fungal; Fluconazole; Humans; In Vitr	2006
Treatment of invasive infections due to rare or emerging yeasts and moulds. Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:9 Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Candidiasis; Clinical Trials as Topic; Dr	2006
[Prophylaxis against mycoses in neutropenic patients]. Mycoses, 1994, Volume: 37 Suppl 2 Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Bone Marrow Transplantation; Candidiasis; Fluconaz	1994
[Role of chemoprophylaxis in the prevention of invasive aspergillosis]. Pathologie-biologie, 1994, Volume: 42, Issue:7 Topics: Aerosols; Amphotericin B; Aspergillosis; Drug Therapy, Combination; Female; Fluconazole; Flucytosine	1994
Aspergillus fumigatus pneumonia in neutropenic patients receiving fluconazole for infection due to Candida species: is amphotericin B combined with fluconazole the appropriate answer? Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1994, Volume: 18, Issue:3 Topics: Amphotericin B; Aspergillosis; Aspergillus fumigatus; Drug Interactions; Drug Therapy, Combination;	1994
Diagnosis and treatment of invasive fungal infections in cancer patients. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 1993, Volume: 1, Issue:5 Topics: Amphotericin B; Aspergillosis; Fluconazole; Humans; Itraconazole; Lung Diseases, Fungal; Mycoses; Ne	1993
Fluconazole and itraconazole: current status and prospects for antifungal therapy. Current clinical topics in infectious diseases, 1993, Volume: 13 Topics: Aspergillosis; Candidiasis; Cryptococcosis; Fluconazole; Humans; Itraconazole; Mycoses	1993
Invasive fungal infections in children: recent advances in diagnosis and treatment. Advances in pediatric infectious diseases, 1996, Volume: 11 Topics: Amphotericin B; Aspergillosis; Candidiasis; Child; Coccidioidomycosis; Cytokines; Diagnosis, Differe	1996
Invasive fungal infections in children: recent advances in diagnosis and treatment. Advances in pediatric infectious diseases, 1996, Volume: 11 Topics: Amphotericin B; Aspergillosis; Candidiasis; Child; Coccidioidomycosis; Cytokines; Diagnosis, Differe	1996
Invasive fungal infections in children: recent advances in diagnosis and treatment. Advances in pediatric infectious diseases, 1996, Volume: 11 Topics: Amphotericin B; Aspergillosis; Candidiasis; Child; Coccidioidomycosis; Cytokines; Diagnosis, Differe	1996
Invasive fungal infections in children: recent advances in diagnosis and treatment. Advances in pediatric infectious diseases, 1996, Volume: 11 Topics: Amphotericin B; Aspergillosis; Candidiasis; Child; Coccidioidomycosis; Cytokines; Diagnosis, Differe	1996
Invasive fungal infections in children: recent advances in diagnosis and treatment. Advances in pediatric infectious diseases, 1996, Volume: 11 Topics: Amphotericin B; Aspergillosis; Candidiasis; Child; Coccidioidomycosis; Cytokines; Diagnosis, Differe	1996
Invasive fungal infections in children: recent advances in diagnosis and treatment. Advances in pediatric infectious diseases, 1996, Volume: 11 Topics: Amphotericin B; Aspergillosis; Candidiasis; Child; Coccidioidomycosis; Cytokines; Diagnosis, Differe	1996
Invasive fungal infections in children: recent advances in diagnosis and treatment. Advances in pediatric infectious diseases, 1996, Volume: 11 Topics: Amphotericin B; Aspergillosis; Candidiasis; Child; Coccidioidomycosis; Cytokines; Diagnosis, Differe	1996
Invasive fungal infections in children: recent advances in diagnosis and treatment. Advances in pediatric infectious diseases, 1996, Volume: 11 Topics: Amphotericin B; Aspergillosis; Candidiasis; Child; Coccidioidomycosis; Cytokines; Diagnosis, Differe	1996
Invasive fungal infections in children: recent advances in diagnosis and treatment. Advances in pediatric infectious diseases, 1996, Volume: 11 Topics: Amphotericin B; Aspergillosis; Candidiasis; Child; Coccidioidomycosis; Cytokines; Diagnosis, Differe	1996
Resistance to antifungal agents in the critical care setting: problems and perspectives. New horizons (Baltimore, Md.), 1996, Volume: 4, Issue:3 Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Candidiasis; Drug Resistance, Microbial; Fluconazo	1996
[Conversion of chronic necrotizing pulmonary aspergillosis to invasive pulmonary aspergillosis, and successful treatment with fluconazole]. Nihon Kyobu Shikkan Gakkai zasshi, 1997, Volume: 35, Issue:4 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antifungal Agents; Arthritis, Rheumatoid; Aspergi	1997
Opportunistic fungal infections: filamentous fungi and cryptococcosis. Geriatrics, 1997, Volume: 52, Issue:10 Topics: Aged; Amphotericin B; Antifungal Agents; Aspergillosis; Cryptococcosis; Fluconazole; Humans; Middle	1997
[New aspects of infections caused by Aspergillus and Mucor and other filamentous fungi in immunosuppressed patients]. Revista clinica espanola, 1995, Volume: 195 Suppl 3 Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Aspergillosis; Bone Marrow	1995
[Prevention and treatment of invasive mycoses in patients with neutropenia and bone marrow transplantation]. Revista clinica espanola, 1995, Volume: 195 Suppl 3 Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Bone Marrow Transplantation; Candidiasis; Candidia	1995
[Diagnosis, treatment and prevention of infections caused by fungi in HIV-positive patients]. Revista clinica espanola, 1995, Volume: 195 Suppl 3 Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Aspergillosis; Cand	1995
[Commonly used antifungal agents in the treatment of systemic mycoses]. Revista clinica espanola, 1995, Volume: 195 Suppl 3 Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Blastomycosis; Candidiasis; Clinical Trials as Top	1995
Prophylaxis of fungal infections. Mycoses, 1997, Volume: 40 Suppl 2 Topics: Antifungal Agents; Aspergillosis; Bone Marrow Transplantation; Candidiasis; Fluconazole; Immunocompr	1997
[Therapy of invasive mycoses in neutropenic patients with hematologic system diseases]. Deutsche medizinische Wochenschrift (1946), 1998, Feb-13, Volume: 123, Issue:7 Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Candidiasis; Chemistry, Pharmaceutical; Fluconazol	1998
The challenge of invasive fungal infection. Chemotherapy, 1999, Volume: 45 Suppl 1 Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Aspergillosis; Candidiasis	1999
Antifungal prophylaxis in neutropenic patients with hematologic malignancies. Antibiotics and chemotherapy, 2000, Volume: 50 Topics: Antifungal Agents; Antineoplastic Agents; Aspergillosis; Aspergillus; Candida; Candidiasis; Fluconaz	2000
Current management of fungal infections. Drugs, 2001, Volume: 61 Suppl 1 Topics: Administration, Oral; Administration, Topical; Amphotericin B; Antifungal Agents; Aspergillosis; Can	2001
Therapy for fungal infections in leukemia. Current oncology reports, 2001, Volume: 3, Issue:3 Topics: Amphotericin B; Aspergillosis; Azoles; Candidiasis; Fluconazole; Humans; Immunotherapy; Leukemia; My	2001
[Choice and use of antifungal drugs]. La Revue du praticien, 2001, Apr-15, Volume: 51, Issue:7 Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Candidiasis; Fluconazole; Flucytosine; Humans; Itr	2001
[Prevention of fungal infections in children and adolescents with cancer]. Klinische Padiatrie, 2001, Volume: 213 Suppl 1 Topics: Administration, Oral; Adolescent; Adult; Age Factors; Amphotericin B; Anemia, Aplastic; Antifungal A	2001
Antifungal prophylaxis in hematopoietic stem cell transplant recipients. Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:11 Suppl 9 Topics: Amphotericin B; Antibiotic Prophylaxis; Antifungal Agents; Aspergillosis; Candidiasis; Fluconazole;	2001
[Therapy of pulmonary mycoses]. Deutsche medizinische Wochenschrift (1946), 1992, Nov-06, Volume: 117, Issue:45 Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Aspergillosis, Allergic Bronchopulmonary; Blastomy	1992
Treatment and developmental therapeutics in aspergillosis. 2. Azoles and other antifungal drugs. Respiration; international review of thoracic diseases, 1992, Volume: 59, Issue:5 Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillosis, Allergic Bronchopulmonary; Azoles; Clotrim	1992
[Systemic mycotic infections]. Recenti progressi in medicina, 1990, Volume: 81, Issue:1 Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Candidiasis; Cryptococcosis; Fluconazole; Humans;	1990

Article	Year
New azole antifungals. 2. Synthesis and antifungal activity of heterocyclecarboxamide derivatives of 3-amino-2-aryl-1-azolyl-2-butanol. Journal of medicinal chemistry, 1998, May-21, Volume: 41, Issue:11 Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Candidiasis; Colony Count, Microbi	1998
New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones. Journal of medicinal chemistry, 1998, May-21, Volume: 41, Issue:11 Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Candidiasis; Colony Count, Microbi	1998
In vivo characterization of A-192411: a novel fungicidal lipopeptide (II). Bioorganic & medicinal chemistry letters, 2003, Feb-10, Volume: 13, Issue:3 Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Candida albicans;	2003
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:3 Topics: Antifungal Agents; Antimicrobial Cationic Peptides; Aspergillosis; Aspergillus; Candida; Candidiasis	2008
In vitro and in vivo antifungal activities of T-2307, a novel arylamidine. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:4 Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Benzamidines; Candida albicans; Ca	2008
Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:3 Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Candida albicans; Candidiasis; Cas	2009
Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors. Bioorganic & medicinal chemistry letters, 2017, 08-01, Volume: 27, Issue:15 Topics: 14-alpha Demethylase Inhibitors; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Azoles; Cy	2017
COVID-19-associated pulmonary aspergillosis (CAPA) in Iranian patients admitted with severe COVID-19 pneumonia. Infection, 2023, Volume: 51, Issue:1 Topics: Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Aspergillosis; Aspergillus; COVID-19; Fe	2023
Antifungal prophylaxis with fluconazole in allogeneic stem cell transplantation recipients who had prior invasive aspergillosis with subsequent complete resolution by computed tomography. Infectious diseases (London, England), 2018, Volume: 50, Issue:4 Topics: Adolescent; Adult; Antibiotic Prophylaxis; Antifungal Agents; Aspergillosis; Feasibility Studies; Fe	2018
Species identification and in vitro antifungal susceptibility testing of Aspergillus section Nigri strains isolated from otomycosis patients. Journal de mycologie medicale, 2018, Volume: 28, Issue:2 Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Aspergillus niger; Clotrimazole; Female;	2018
Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:11 Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Calcineurin; Calcineurin Inhibitor	2018
Aspergillus felis sp. nov., an emerging agent of invasive aspergillosis in humans, cats, and dogs. PloS one, 2013, Volume: 8, Issue:6 Topics: Air Microbiology; Animals; Antifungal Agents; Aspergillosis; Aspergillus; Caspofungin; Cat Diseases;	2013
Dried blood spot analysis suitable for therapeutic drug monitoring of voriconazole, fluconazole, and posaconazole. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:10 Topics: Adult; Aged; Antifungal Agents; Aspergillosis; Dried Blood Spot Testing; Drug Monitoring; Fluconazol	2013
How much European prescribing physicians know about invasive fungal infections management? BMC infectious diseases, 2015, Feb-21, Volume: 15 Topics: Adult; Antifungal Agents; Aspergillosis; Candidiasis, Invasive; Cross-Sectional Studies; Europe; Fem	2015
Mycetoma Caused by Aspergillus nidulans. Acta dermato-venereologica, 2016, Volume: 96, Issue:1 Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Aspergillus nidulans; Biopsy; DNA, Fungal; Drug Su	2016
Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high-risk liver transplantation recipients: A propensity score analysis. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2016, Volume: 22, Issue:4 Topics: Adult; Aged; Alanine Transaminase; Antifungal Agents; Aspergillosis; Bilirubin; Caspofungin; Cohort	2016
Acute isolated appendicitis due to Aspergillus carneus in a neutropenic child with acute myeloid leukemia. The new microbiologica, 2016, Volume: 39, Issue:1 Topics: Acute Disease; Acyclovir; Amphotericin B; Antifungal Agents; Appendicitis; Aspergillosis; Aspergillu	2016
Treatment of aspergillosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Aug-01, Volume: 47, Issue:3 Topics: Antifungal Agents; Aspergillosis; Fluconazole; Humans; Itraconazole; Leukemia, Myeloid, Acute; Myelo	2008
Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. The Annals of pharmacotherapy, 2008, Volume: 42, Issue:11 Topics: Aged; Antifungal Agents; Aspergillosis; Drug Interactions; Everolimus; Fatal Outcome; Fluconazole; H	2008
Aspergillus otomycosis in an immunocompromised patient. Ear, nose, & throat journal, 2008, Volume: 87, Issue:11 Topics: Antifungal Agents; Aspergillosis; Aspergillus niger; Clotrimazole; Earache; Fluconazole; Humans; Imm	2008
Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation. Transplantation proceedings, 2008, Volume: 40, Issue:9 Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Aged; Amphotericin B; Antifunga	2008
Aspergillosis of biliary tract after liver transplantation: a case report. Mycopathologia, 2010, Volume: 170, Issue:2 Topics: Aspergillosis; Aspergillus flavus; Biliary Tract; Chemoprevention; Drug Resistance, Fungal; Fatal Ou	2010
Aspergillus fumigatus Meningitis in a Preterm. Indian pediatrics, 2010, Volume: 47, Issue:11 Topics: Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Fluconazole; Humans; Infant, Extremely Low	2010
Antifungal activity of essential oils and their synergy with fluconazole against drug-resistant strains of Aspergillus fumigatus and Trichophyton rubrum. Applied microbiology and biotechnology, 2011, Volume: 90, Issue:3 Topics: Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Drug Resistance, Fungal; Fluconazole; Gas C	2011
Invasive fungal infections in pediatric patients with hematologic malignancies receiving oral amphotericin B solution and early intravenous administration of fluconazole. Journal of pediatric hematology/oncology, 2011, Volume: 33, Issue:4 Topics: Administration, Oral; Adolescent; Amphotericin B; Antifungal Agents; Antineoplastic Agents; Aspergil	2011
Use of antifungal agents in pediatric and adult high-risk areas. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2012, Volume: 31, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Aspergillosis; Asperg	2012
SREBP-dependent triazole susceptibility in Aspergillus fumigatus is mediated through direct transcriptional regulation of erg11A (cyp51A). Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:1 Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Cytochrome P-450 Enzyme System; Dr	2012
Recurrent fungal iris granuloma in a 10-year-old child. Ocular immunology and inflammation, 2012, Volume: 20, Issue:3 Topics: Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Child; Drug Therapy, Combination; Eye Infec	2012
A novel case of canine disseminated aspergillosis following mating. The Canadian veterinary journal = La revue veterinaire canadienne, 2012, Volume: 53, Issue:2 Topics: Animals; Antifungal Agents; Aspergillosis; Copulation; Dog Diseases; Dogs; Fatal Outcome; Female; Fl	2012
Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002, Aug-01, Volume: 35, Issue:3 Topics: Adult; Amphotericin B; Anti-Bacterial Agents; Antifungal Agents; Aspergillosis; Bone Marrow Transpla	2002
Fungal infections in marrow transplant recipients under antifungal prophylaxis with fluconazole. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2002, Volume: 35, Issue:7 Topics: Adolescent; Adult; Antifungal Agents; Aspergillosis; Bone Marrow Transplantation; Candidiasis; Femal	2002
Two cases of Aspergillus sinusitis with bone destruction. Auris, nasus, larynx, 2003, Volume: 30 Suppl Topics: Aged; Aspergillosis; Cranial Nerve Diseases; Disease Progression; Ethmoid Sinus; Ethmoid Sinusitis;	2003
Confocal microscopy of Aspergillus fumigatus keratitis. The British journal of ophthalmology, 2003, Volume: 87, Issue:4 Topics: Administration, Oral; Administration, Topical; Animals; Antifungal Agents; Aspergillosis; Aspergillu	2003
Aspergillosis: a rare case of secondary delayed mandibular involvement. Quintessence international (Berlin, Germany : 1985), 2003, Volume: 34, Issue:2 Topics: Adult; Amphotericin B; Antifungal Agents; Aspergillosis; Female; Fluconazole; Humans; Mandibular Dis	2003
[Invasive cerebral aspergillosis in an immunocompetent patient: a case report]. No to shinkei = Brain and nerve, 2003, Volume: 55, Issue:2 Topics: Adult; Amphotericin B; Antifungal Agents; Aspergillosis; Brain Diseases; Female; Fluconazole; Humans	2003
Adult onset anaphylactoid purpura with severe gastrointestinal involvement. Internal medicine (Tokyo, Japan), 2003, Volume: 42, Issue:5 Topics: Age of Onset; Aged; Antifungal Agents; Antirheumatic Agents; Aspergillosis; Cyclophosphamide; Fatal	2003
Disseminated aspergillosis due to Aspergillus flavus in an experimental model: efficacy of azole therapy. Mycoses, 2003, Volume: 46, Issue:5-6 Topics: Administration, Oral; Animals; Antifungal Agents; Aspergillosis; Aspergillus flavus; Brain; Colony C	2003
Comparison of efficacy of topical and oral fluconazole treatment in experimental Aspergillus keratitis. Current eye research, 2003, Volume: 26, Issue:2 Topics: Administration, Oral; Administration, Topical; Animals; Antifungal Agents; Aspergillosis; Aspergillu	2003
[Antifungal activity and clinical efficacy of micafungin sodium (Funguard)]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2003, Volume: 122, Issue:4 Topics: Adult; Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Aspergillus; Candida; Candidiasis;	2003
[A case of rapidly progressing pulmonary aspergillosis presenting various forms of shadow]. Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 2003, Volume: 41, Issue:8 Topics: Aged; Aspergillosis; Aspergillus; Chronic Disease; Disease Progression; Female; Fluconazole; Humans;	2003
Fungal infection of sutureless self-sealing incision for cataract surgery. Ophthalmology, 2003, Volume: 110, Issue:11 Topics: Aged; Aged, 80 and over; Amphotericin B; Aspergillosis; Candidiasis; Corneal Ulcer; Drug Therapy, Co	2003
[New strategy of treatment for deep-seated mycosis]. The Japanese journal of antibiotics, 2004, Volume: 57, Issue:2 Topics: Antifungal Agents; Aspergillosis; Fluconazole; Humans; Mycoses; Serologic Tests	2004
A case of primary cutaneous aspergillosis in a renal transplant recipient. Transplantation proceedings, 2004, Volume: 36, Issue:7 Topics: Antifungal Agents; Aspergillosis; Fluconazole; Humans; Immunocompromised Host; Kidney Failure, Chron	2004
Phototherapeutic keratectomy in treating keratomycosis. Cornea, 2005, Volume: 24, Issue:3 Topics: Adolescent; Adult; Aged; Amphotericin B; Antifungal Agents; Aspergillosis; Aspergillus; Child; Corne	2005
Necrotic ulcer on the thumb of a teenager with leukemia. Archives of dermatology, 2005, Volume: 141, Issue:5 Topics: Adolescent; Amphotericin B; Antifungal Agents; Aspergillosis; Aspergillus flavus; Dermatomycoses; Fa	2005
Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science (New York, N.Y.), 2005, Sep-30, Volume: 309, Issue:5744 Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Aspergillosis; Aspergillus; Biological Evo	2005
Invasive pulmonary aspergillosis and pulmonary cryptococcosis really coexist in immunocompromised host. The Journal of infection, 2006, Volume: 53, Issue:2 Topics: Adult; Amphotericin B; Antifungal Agents; Aspergillosis; Cryptococcosis; Female; Fluconazole; Humans	2006
Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates: a single-center, 6-year, retrospective cohort study. Pediatrics, 2006, Volume: 117, Issue:1 Topics: Antifungal Agents; Aspergillosis; Candida; Candidiasis; Fluconazole; Humans; Infant, Newborn; Infant	2006
[Pulmonary fungal infection in malignant hematological diseases: an analysis of 14 cases]. Zhongguo shi yan xue ye xue za zhi, 2005, Volume: 13, Issue:6 Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Candidiasis; Female; Fluconazole; Hematol	2005
Role of prospective screening of blood for invasive aspergillosis by polymerase chain reaction in febrile neutropenic recipients of haematopoietic stem cell transplants and patients with acute leukaemia. British journal of haematology, 2006, Volume: 132, Issue:4 Topics: Acute Disease; Adolescent; Adult; Antifungal Agents; Aspergillosis; Aspergillus; DNA, Fungal; Female	2006
In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:6 Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Aspergillus; Candida; Candidiasis; Cryptococcosis;	2006
Aspergillus meningitis following spinal anaesthesia for caesarean section in Colombo, Sri Lanka. International journal of obstetric anesthesia, 2007, Volume: 16, Issue:3 Topics: Abducens Nerve Diseases; Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Antifungal Agents; Aspe	2007
Prophylaxis and aspergillosis--has the principle been proven? The New England journal of medicine, 2007, Jan-25, Volume: 356, Issue:4 Topics: Antifungal Agents; Aspergillosis; Fluconazole; Graft vs Host Disease; Humans; Itraconazole; Mycoses;	2007
Posaconazole. Nature reviews. Drug discovery, 2007, Volume: 6, Issue:3 Topics: Administration, Oral; Antifungal Agents; Aspergillosis; Candidiasis; Capsules; Drug Approval; Drug D	2007
Presumptive treatment strategy for aspergillosis in allogeneic haematopoietic stem cell transplant recipients. The Journal of antimicrobial chemotherapy, 2007, Volume: 60, Issue:2 Topics: Adult; Aged; Antifungal Agents; Aspergillosis; Endpoint Determination; Female; Fluconazole; Hematopo	2007
Voriconazole: a broad spectrum triazole for the treatment of serious and invasive fungal infections. Future microbiology, 2006, Volume: 1, Issue:4 Topics: Administration, Oral; Antifungal Agents; Aspergillosis; Candidiasis; Drug Evaluation; Drug Resistanc	2006
[Clinical features and treatment of invasive fungal infection in 47 patients with hematological malignancies]. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2008, Volume: 33, Issue:1 Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Candidiasis; Female; Fluconazole; Hematol	2008
[Clinical cases in medical mycology. Case no. 32]. Revista iberoamericana de micologia, 2008, Volume: 25, Issue:1 Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Aspergillosis; Bacteremia; Bronchoalveolar	2008
Chemosensitization prevents tolerance of Aspergillus fumigatus to antimycotic drugs. Biochemical and biophysical research communications, 2008, Jul-18, Volume: 372, Issue:1 Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Benzaldehydes; Catechols; C	2008
In vitro and in vivo antifungal activities of DU-6859a, a fluoroquinolone, in combination with amphotericin B and fluconazole against pathogenic fungi. Antimicrobial agents and chemotherapy, 1995, Volume: 39, Issue:7 Topics: Amphotericin B; Animals; Anti-Infective Agents; Antifungal Agents; Aspergillosis; Aspergillus fumiga	1995
Aspergillus brain abscess in a patient with normal immunity--case report. Neurologia medico-chirurgica, 1994, Volume: 34, Issue:4 Topics: Amphotericin B; Aspergillosis; Brain Abscess; Combined Modality Therapy; Fluconazole; Frontal Lobe;	1994
Deadly fungal infections spreading in cancer patients. Journal of the National Cancer Institute, 1995, Oct-04, Volume: 87, Issue:19 Topics: Antineoplastic Agents; Aspergillosis; Candidiasis; Fluconazole; Humans; Mycoses; Neoplasms; Opportun	1995
[Pharmacokinetics of transbronchially injected flconazole in pulmonary aspergillosis]. Nihon Kyobu Shikkan Gakkai zasshi, 1995, Volume: 33, Issue:2 Topics: Aged; Aspergillosis; Bronchi; Epithelium; Female; Fluconazole; Humans; Injections, Intralesional; Lu	1995
Endogenous Aspergillus endophthalmitis associated with periodontitis. Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 1995, Volume: 209, Issue:2 Topics: Aspergillosis; Aspergillus flavus; Endophthalmitis; Eye Infections, Fungal; Female; Fluconazole; Hum	1995
What is your neurologic diagnosis? An atypical case of diskspondylitis caused by Aspergillus spp. Journal of the American Veterinary Medical Association, 1995, May-01, Volume: 206, Issue:9 Topics: Animals; Aspergillosis; Discitis; Dog Diseases; Dogs; Fatal Outcome; Female; Fluconazole; Lumbar Ver	1995
When to use fluconazole. Lancet (London, England), 1995, Mar-04, Volume: 345, Issue:8949 Topics: AIDS-Related Opportunistic Infections; Aspergillosis; Candidiasis; Drug Resistance, Microbial; Fluco	1995
[Percutaneous intracavitary treatment of pulmonary aspergilloma-clinical efficacy and prognosis]. Nihon Kyobu Shikkan Gakkai zasshi, 1994, Volume: 32, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Aspergillosis; Female; Fluconazol	1994
[Invasive bronchopulmonary aspergillosis treated with itraconazole in a patient with acute leukemia]. Sangre, 1993, Volume: 38, Issue:5 Topics: Agranulocytosis; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Bone	1993
Prevention of invasive fungal infection during chemotherapy-induced neutropenia in patients with acute leukemia. Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases, 1994, Volume: 68, Issue:3 Topics: Acute Disease; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Aged; Amphoteric	1994
Successful bone marrow transplantation in patients with previous invasive fungal infections: report of four cases. Bone marrow transplantation, 1994, Volume: 13, Issue:3 Topics: Administration, Oral; Adolescent; Adult; Amphotericin B; Aspergillosis; Aspergillus; Bone Marrow Tra	1994
A study of fungal infections in otorhinolaryngology. Acta oto-laryngologica. Supplementum, 1994, Volume: 511 Topics: Adult; Aspergillosis; Aspergillus; Candida; Fluconazole; Humans; Japan; Male; Middle Aged; Mycoses;	1994
Combination therapy in experimental invasive aspergillosis. The Journal of infectious diseases, 1993, Volume: 168, Issue:3 Topics: Amphotericin B; Animals; Antigens, Fungal; Aspergillosis; Disease Models, Animal; Drug Therapy, Comb	1993
Fluconazole in patients at risk from invasive aspergillosis. Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology, 1993, Volume: 31, Issue:3 Topics: Adult; Agranulocytosis; Aspergillosis; Female; Fluconazole; Humans; Immunosuppression Therapy; Male;	1993
Topical treatment of pulmonary aspergilloma by antifungals. Relationship between duration of the disease and efficacy of therapy. Chest, 1993, Volume: 103, Issue:5 Topics: Aged; Amphotericin B; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Aspergillus niger; Fe	1993
Correlation of cilofungin in vivo efficacy with its activity against Aspergillus fumigatus (1,3)-beta-D-glucan synthase. FEMS microbiology letters, 1993, Apr-01, Volume: 108, Issue:2 Topics: Amphotericin B; Animals; Aspergillosis; Aspergillus fumigatus; Dose-Response Relationship, Drug; Ech	1993
Aspergillus fumigatus pneumonia in neutropenic patients during therapy with fluconazole for infection due to Candida species. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1993, Volume: 16, Issue:5 Topics: Adolescent; Adult; Aged; Aspergillosis; Aspergillus fumigatus; Candidiasis; Female; Fluconazole; Hum	1993
[Two cases of Aspergillus endocarditis after cardiac surgery in childhood]. Kyobu geka. The Japanese journal of thoracic surgery, 1996, Volume: 49, Issue:8 Suppl Topics: Antifungal Agents; Aspergillosis; Child, Preschool; Endocarditis; Female; Fluconazole; Humans; Male;	1996
Aspergillus fumigatus scleritis. Acta ophthalmologica Scandinavica, 1995, Volume: 73, Issue:5 Topics: Aged; Amphotericin B; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Cryotherapy; Dura Mat	1995
In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Antimicrobial agents and chemotherapy, 1996, Volume: 40, Issue:10 Topics: Animals; Antifungal Agents; Aspergillosis; Candidiasis; Cryptococcosis; Female; Fluconazole; Fungi;	1996
Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis. Antimicrobial agents and chemotherapy, 1996, Volume: 40, Issue:10 Topics: Animals; Antifungal Agents; Aspergillosis; Brain Diseases; Candidiasis; Candidiasis, Oral; Cryptococ	1996
Empyema following the percutaneous instillation of antifungal agents in patients with aspergillosis. Internal medicine (Tokyo, Japan), 1996, Volume: 35, Issue:8 Topics: Aged; Amphotericin B; Antifungal Agents; Aspergillosis; Empyema; Fluconazole; Humans; Injections; Lu	1996
Suspected drug eruption in seven dogs during administration of flucytosine. Australian veterinary journal, 1996, Volume: 74, Issue:4 Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Cryptococcosis; Dog Diseases; Dogs; Drug	1996
T-8581, a new orally and parenterally active triazole antifungal agent: in vitro and in vivo evaluations. Antimicrobial agents and chemotherapy, 1997, Volume: 41, Issue:1 Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Candida; Candidiasis; Cryptococcus	1997
The in-vivo activity of an antifungal antibiotic, benanomicin A, in comparison with amphotericin B and fluconazole. The Journal of antimicrobial chemotherapy, 1997, Volume: 39, Issue:1 Topics: Amphotericin B; Animals; Anthracyclines; Antibiotics, Antineoplastic; Antifungal Agents; Aspergillos	1997
Early surgical management of invasive gingival aspergillosis in a neutropenic patient with leukemia: a case report. International journal of oral and maxillofacial surgery, 1997, Volume: 26, Issue:1 Topics: Adult; Amphotericin B; Antifungal Agents; Aspergillosis; Female; Fluconazole; Flucytosine; Gingival	1997
Detection and identification of fungal pathogens in blood by using molecular probes. Journal of clinical microbiology, 1997, Volume: 35, Issue:6 Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Aspergillus; Candida; Candidiasis; DNA, Fungal; Fl	1997
Systemic antifungal drugs. The Medical letter on drugs and therapeutics, 1997, Sep-12, Volume: 39, Issue:1009 Topics: Amphotericin B; Anorexia; Antifungal Agents; Aspergillosis; Blastomycosis; Candidiasis; Coccidioidom	1997
[Successful use of fluconazole against semi-invasive--pulmonary aspergillosis]. Nihon Kyobu Shikkan Gakkai zasshi, 1997, Volume: 35, Issue:6 Topics: Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Fluconazole; Humans; Lung Diseases, Fungal;	1997
[Invasive pulmonary aspergillosis: a study of 33 cases]. Medicina clinica, 1998, Mar-28, Volume: 110, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Aspergillosis; Cross Infection; Female; Fluconazo	1998
Antifungal susceptibility of Aspergillus species isolated from invasive oral infection in neutropenic patients with hematologic malignancies. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 1999, Volume: 87, Issue:2 Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Antineoplastic Agents; Aspergillosis; Aspergillus; D	1999
Chronic Aspergillus sp. meningitis successfully treated with fluconazole. Case report. Arquivos de neuro-psiquiatria, 1999, Volume: 57, Issue:2A Topics: Adult; Antibodies, Fungal; Antifungal Agents; Aspergillosis; Chronic Disease; Female; Fluconazole; H	1999
[Anesthetic management for transtracheal placement of a catheter for intracavity infusion of an antifungal drug in patients with pulmonary fungus ball of aspergillosis]. Masui. The Japanese journal of anesthesiology, 1999, Volume: 48, Issue:11 Topics: Aged; Anesthesia, General; Antifungal Agents; Aspergillosis; Catheterization; Female; Fluconazole; H	1999
Value of Ga-67 SPECT in monitoring the effects of therapy in invasive aspergillosis of the sphenoid sinus. Clinical nuclear medicine, 1999, Volume: 24, Issue:12 Topics: Aged; Amphotericin B; Antifungal Agents; Aspergillosis; Brain; Diagnosis, Differential; Fluconazole;	1999
Itraconazole verus fluconazole in neutropenic patients. British journal of haematology, 2000, Volume: 108, Issue:1 Topics: Antifungal Agents; Aspergillosis; Fluconazole; Humans; Itraconazole; Neutropenia	2000
[Aspergillus spondylodiscitis]. Revue neurologique, 2000, Volume: 156, Issue:2 Topics: Adult; Amanita; Antifungal Agents; Aspergillosis; Discitis; Eye Infections, Fungal; Fluconazole; Hum	2000
[Therapy of deep seated mycoses--Timing of administration and selection of antifungal agents]. The Japanese journal of antibiotics, 2000, Volume: 53, Issue:2 Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Candidiasis; Fluconazole; Humans; Immunoc	2000
[Two cases of pulmonary aspergillosis successfully treated with multidrug therapy]. The Japanese journal of antibiotics, 2000, Volume: 53, Issue:2 Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Drug Therapy, Combination; Fluconazole; Flucytosin	2000
[Four cases of pulmonary aspergilloma successfully treated with drug therapy]. The Japanese journal of antibiotics, 2000, Volume: 53, Issue:2 Topics: Administration, Inhalation; Administration, Oral; Aged; Aged, 80 and over; Amphotericin B; Antifunga	2000
Study on the hyphal responses of Aspergillus fumigatus to the antifungal agent by Bio-Cell Tracer. Mycopathologia, 1999, Volume: 148, Issue:1 Topics: Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Bioreactors; Fluconazole; Humans; Videotape	1999
Reply to Dr. Chandrasekar (Clin Infect Dis 2001; 32:320-1) and Drs. Marr and Boeckh (Clin Infect Dis 2001; 32:321). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2001, Feb-01, Volume: 32, Issue:3 Topics: Antifungal Agents; Aspergillosis; Fever of Unknown Origin; Fluconazole; Humans; Neutropenia	2001
Laryngeal aspergillosis. Ear, nose, & throat journal, 2001, Volume: 80, Issue:5 Topics: Adolescent; Antifungal Agents; Aspergillosis; Combined Modality Therapy; Female; Fluconazole; Humans	2001
Liposomal nystatin (L-NYS) in therapy of pulmonary aspergillosis refractory to conventional amphotericin B in cancer patients. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2001, Volume: 9, Issue:3 Topics: Adolescent; Adult; Amphotericin B; Antifungal Agents; Aspergillosis; Child; Female; Fluconazole; Hum	2001
[Endogenous fungal endophthalmitis: results of antifungal treatment with and without vitrectomy]. Klinische Monatsblatter fur Augenheilkunde, 2001, Volume: 218, Issue:5 Topics: Adult; Aged; Aspergillosis; Candidiasis; Combined Modality Therapy; Enophthalmos; Female; Fluconazol	2001
Case report. Hepatic abscesses due to Aspergillus terreus in an immunodeficient child. Mycoses, 2001, Volume: 44, Issue:9-10 Topics: Adolescent; Amphotericin B; Antifungal Agents; Aspergillosis; Candida; Candidiasis; Drug Therapy, Co	2001
Itraconazole prophylaxis for invasive gingival aspergillosis in neutropenic patients with acute leukemia. Journal of periodontology, 2002, Volume: 73, Issue:1 Topics: Administration, Oral; Amphotericin B; Antifungal Agents; Aspergillosis; Candidiasis, Oral; Capsules;	2002
Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study involving 720 patients with haematological malignancy. British journal of haematology, 2002, Volume: 117, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Aspergillosis; Autopsy; Candidiasis;	2002
Technetium-99m labelled fluconazole and antimicrobial peptides for imaging of Candida albicans and Aspergillus fumigatus infections. European journal of nuclear medicine and molecular imaging, 2002, Volume: 29, Issue:5 Topics: Animals; Aspergillosis; Aspergillus fumigatus; Candidiasis; Diagnosis, Differential; Fluconazole; Hu	2002
Invasive subglottal aspergillosis in a patient with severe aplastic anemia: a case report. The Journal of infection, 2002, Volume: 44, Issue:3 Topics: Adult; Amphotericin B; Anemia, Aplastic; Anti-Inflammatory Agents; Antifungal Agents; Aspergillosis;	2002
Locally invasive pulmonary aspergillosis in a healthy man successfully treated with oral fluconazole. Internal medicine (Tokyo, Japan), 1992, Volume: 31, Issue:12 Topics: Administration, Oral; Aged; Aspergillosis; Fluconazole; Humans; Lung Diseases, Fungal; Male; Tomogra	1992
The evaluation of therapeutic responses in experimental keratomycosis. Current eye research, 1992, Volume: 11, Issue:1 Topics: Administration, Oral; Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Colony Count	1992
In vitro antifungal spectrum of itraconazole and treatment of systemic mycoses with old and new antimycotic agents. Chemotherapy, 1992, Volume: 38 Suppl 1 Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Candidiasis; Cryptococcosis; Drug Therapy	1992
[Sphenoid sinus aspergillosis presenting abducens nerve palsy and visual field impairment; a case report]. No shinkei geka. Neurological surgery, 1992, Volume: 20, Issue:7 Topics: Abducens Nerve; Aged; Antifungal Agents; Aspergillosis; Cranial Nerve Diseases; Female; Fluconazole;	1992
Surveillance and treatment of liver transplant recipients for candidiasis and aspergillosis. European journal of epidemiology, 1992, Volume: 8, Issue:3 Topics: Adolescent; Adult; Amphotericin B; Aspergillosis; Candidiasis; Child; Child, Preschool; Fluconazole;	1992
Comparison of SCH 39304, fluconazole, and ketoconazole for treatment of systemic infections in mice. Antimicrobial agents and chemotherapy, 1992, Volume: 36, Issue:1 Topics: Administration, Oral; Animals; Antifungal Agents; Aspergillosis; Candidiasis; Drug Evaluation, Precl	1992
[Percutaneous instillation of fluconazole in the treatment of pulmonary aspergilloma]. Nihon Kyobu Shikkan Gakkai zasshi, 1991, Volume: 29, Issue:10 Topics: Administration, Cutaneous; Aged; Aspergillosis; Female; Fluconazole; Humans; Injections, Intralesion	1991
[Effect of fluconazole on Aspergillus infection associated with chronic granulomatous disease]. Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases, 1991, Volume: 65, Issue:9 Topics: Aspergillosis; Aspergillus fumigatus; Child, Preschool; Fluconazole; Granulomatous Disease, Chronic;	1991
The role of fluconazole in the early treatment and prophylaxis of experimental invasive aspergillosis. The Journal of infectious diseases, 1991, Volume: 164, Issue:3 Topics: Animals; Aspergillosis; Aspergillus fumigatus; Disease Models, Animal; Drug Evaluation, Preclinical;	1991
[Drug therapy of intractable mycoses]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1990, Dec-10, Volume: 79, Issue:12 Topics: Administration, Oral; Amphotericin B; Aspergillosis; Candidiasis; Cryptococcosis; Fluconazole; Flucy	1990
Orally administered antifungal therapy for experimental keratomycosis. Transactions of the American Ophthalmological Society, 1990, Volume: 88 Topics: Administration, Oral; Animals; Aspergillosis; Aspergillus fumigatus; Candida albicans; Candidiasis;	1990
[Prophylaxis and therapy of fungal infections with fluconazole in patients after bone marrow transplantation]. Mycoses, 1990, Volume: 33 Suppl 1 Topics: Adult; Aspergillosis; Bone Marrow Transplantation; Candidiasis; Female; Fluconazole; Humans; Male; M	1990
Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis. Antimicrobial agents and chemotherapy, 1990, Volume: 34, Issue:3 Topics: Administration, Oral; Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Candidiasis; Crypto	1990
Pulmonary aspergillosis in mice: treatment with a new triazole SCH39304. The American review of respiratory disease, 1990, Volume: 142, Issue:3 Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Female; Fluconazol	1990
In vivo efficacy of SM-8668 (Sch 39304), a new oral triazole antifungal agent. Antimicrobial agents and chemotherapy, 1990, Volume: 34, Issue:6 Topics: Administration, Cutaneous; Administration, Oral; Animals; Antifungal Agents; Aspergillosis; Aspergil	1990
Short-term curative treatment of Aspergillus fumigatus pneumonia with fluconazole. Scandinavian journal of infectious diseases, 1990, Volume: 22, Issue:6 Topics: Aged; Aspergillosis; Aspergillus fumigatus; Female; Fluconazole; Humans; Lung Diseases, Fungal; Pneu	1990
Fluconazole. The Journal of infection, 1990, Volume: 21, Issue:1 Topics: Acquired Immunodeficiency Syndrome; Animals; Aspergillosis; Candidiasis, Chronic Mucocutaneous; Cryp	1990
[The clinical study of fluconazole against pulmonary mycosis. Effects of fluconazole on pulmonary cryptococcosis and aspergillosis, and its pharmacokinetics in patients]. The Japanese journal of antibiotics, 1989, Volume: 42, Issue:1 Topics: Adult; Aged; Antifungal Agents; Aspergillosis; Cryptococcosis; Drug Evaluation; Fluconazole; Half-Li	1989
[Clinical efficacy of fluconazole in the patient with pulmonary mycosis]. The Japanese journal of antibiotics, 1989, Volume: 42, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antifungal Agents; Aspergillosis; Cr	1989
[Clinical evaluation of fluconazole in patients with mycotic infection]. The Japanese journal of antibiotics, 1989, Volume: 42, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Aspergillosis; Aspergillus; Candidiasis; Candidia	1989
[A clinical study of fluconazole in pulmonary aspergillosis]. The Japanese journal of antibiotics, 1989, Volume: 42, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Fungal; Antifungal Agents; Aspergi	1989
Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice. Chemotherapy, 1987, Volume: 33, Issue:5 Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Candidiasis; Cryptococcosis; Drug Therapy	1987
Efficacy of fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice. The Journal of antimicrobial chemotherapy, 1987, Volume: 19, Issue:5 Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillosis; Aspergillus flavus; Aspergillus fumigatus	1987

fluconazole and Aspergillosis

Research Excerpts

Research

Studies (194)

Authors

Clinical Trials (11)

Trial Overview

Trial Outcomes

Overall Survival

Percentage of Participants That Need Empiric Antifungal Therapy

Percentage of Participants With Proven or Probable Invasive Aspergillosis (IA)

Percentage of Participants With Proven or Probable Invasive Fungal Infections (IFI)

Failure to Engraft

Frequency of Invasive Fungal Infections (IFI)

Frequency of Use of Amphotericin B or Caspofungin

Fungal-free Survival (Percentage of Participants Alive and Free From Proven, Probable, or Presumptive Invasive Fungal Infection) at 180 Days Post-transplant

Duration of Use of Amphotericin B or Caspofungin

Freedom From Possible, Presumptive, Probable, or Proven Invasive Fungal Infection, Death, or Withdrawal of Study Drug Due to Toxicity, Intolerance, or an Empirical Trial of Amphotericin B or Caspofungin Greater Than 14 Consecutive Days

Overall Survival

Percentage of Patients With Invasive Fungal Infection at 100, 180, and 365 Days

Relapse Free Survival

Time to and Severity of Acute and Chronic Graft vs Host Disease (GVHD)

Utility of Galactomannan Assay in Diagnosis of Aspergillus and Response to Therapy

Efficacy of Primary Prophylaxis With Nebulized Abelcet® on the Incidence of Invasive Pulmonary Aspergillosis

Invasive Pulmonary Aspergillosis -Related Mortality During Primary Prophylaxis With Abelcet®.

Number of Participants With Adverse Events That Results in the Interruption of Treatment, as a Measure of Safety and Tolerability

Reviews

Trials

Other Studies

Article	Year
Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial. JAMA, 2019, 11-05, Volume: 322, Issue:17 Topics: Adolescent; Adult; Antifungal Agents; Aspergillosis; Caspofungin; Child; Child, Preschool; Early Ter	2019
Benefits of risk-adapted and mould-specific antifungal prophylaxis in childhood leukaemia. British journal of haematology, 2020, Volume: 191, Issue:5 Topics: Amphotericin B; Aspergillosis; Aspergillus; Child; Child, Preschool; Female; Fluconazole; Humans; Le	2020
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood, 2010, Dec-09, Volume: 116, Issue:24 Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Child; Child, Preschool; Disease-Free Sur	2010
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood, 2010, Dec-09, Volume: 116, Issue:24 Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Child; Child, Preschool; Disease-Free Sur	2010
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood, 2010, Dec-09, Volume: 116, Issue:24 Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Child; Child, Preschool; Disease-Free Sur	2010
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood, 2010, Dec-09, Volume: 116, Issue:24 Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Child; Child, Preschool; Disease-Free Sur	2010
Antifungal prophylaxis in liver transplant recipients: a randomized placebo-controlled study. Transplant international : official journal of the European Society for Organ Transplantation, 2002, Volume: 15, Issue:7 Topics: Adult; Amphotericin B; Antifungal Agents; Aspergillosis; Candidiasis; Drug Administration Schedule;	2002
Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. American journal of hematology, 2002, Volume: 71, Issue:4 Topics: Adolescent; Adult; Amphotericin B; Antifungal Agents; Aspergillosis; Bone Marrow Transplantation; Ca	2002
Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood, 2004, Feb-15, Volume: 103, Issue:4 Topics: Adult; Antifungal Agents; Aspergillosis; Drug Resistance, Fungal; Female; Fluconazole; Graft vs Host	2004
Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood, 2004, Feb-15, Volume: 103, Issue:4 Topics: Adult; Antifungal Agents; Aspergillosis; Drug Resistance, Fungal; Female; Fluconazole; Graft vs Host	2004
Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood, 2004, Feb-15, Volume: 103, Issue:4 Topics: Adult; Antifungal Agents; Aspergillosis; Drug Resistance, Fungal; Female; Fluconazole; Graft vs Host	2004
Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood, 2004, Feb-15, Volume: 103, Issue:4 Topics: Adult; Antifungal Agents; Aspergillosis; Drug Resistance, Fungal; Female; Fluconazole; Graft vs Host	2004
Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2005, Jun-15, Volume: 40, Issue:12 Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Aspergillus; Child; False Negative Reacti	2005
An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. The Journal of antimicrobial chemotherapy, 2006, Volume: 57, Issue:2 Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Double-Blind Method; Endpoint Determinati	2006
A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. Bone marrow transplantation, 2006, Volume: 38, Issue:2 Topics: Acute Disease; Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Drug Administration Schedu	2006
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. The New England journal of medicine, 2007, Jan-25, Volume: 356, Issue:4 Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Double-Blind Method; Female; Fluconazole;	2007
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. The New England journal of medicine, 2007, Jan-25, Volume: 356, Issue:4 Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Double-Blind Method; Female; Fluconazole;	2007
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. The New England journal of medicine, 2007, Jan-25, Volume: 356, Issue:4 Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Double-Blind Method; Female; Fluconazole;	2007
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. The New England journal of medicine, 2007, Jan-25, Volume: 356, Issue:4 Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Double-Blind Method; Female; Fluconazole;	2007
Antifungal usage in children undergoing intensive treatment for acute myeloid leukemia: analysis of the multicenter clinical trial AML-BFM 93. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2007, Volume: 26, Issue:10 Topics: Adolescent; Amphotericin B; Antifungal Agents; Aspergillosis; Candidiasis; Child; Female; Fluconazol	2007
Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. The Journal of infectious diseases, 1995, Volume: 172, Issue:4 Topics: Adult; Amphotericin B; Antibiotic Prophylaxis; Antifungal Agents; Aspergillosis; Bacteremia; Candidi	1995
An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy. Annals of hematology, 1995, Volume: 70, Issue:2 Topics: Administration, Oral; Adolescent; Adult; Aged; Aspergillosis; Aspergillus fumigatus; Candidiasis; Fe	1995
[Usefulness of percutaneous instillation of antifungal agents for pulmonary aspergilloma]. Kekkaku : [Tuberculosis], 1995, Volume: 70, Issue:1 Topics: Aged; Aged, 80 and over; Antifungal Agents; Aspergillosis; Female; Fluconazole; Humans; Instillation	1995
[A clinical study on fluconazole against pulmonary mycosis associated with respiratory diseases]. The Japanese journal of antibiotics, 1994, Volume: 47, Issue:9 Topics: Adult; Aged; Aspergillosis; Candidiasis; Cryptococcosis; Female; Fluconazole; Humans; Lung Diseases,	1994
[Clinical study of fluconazole-injectable and -granules in pediatric patients]. The Japanese journal of antibiotics, 1994, Volume: 47, Issue:3 Topics: Administration, Oral; Anemia, Aplastic; Aspergillosis; Candidiasis; Fluconazole; Humans; Injections,	1994
[Experience of fluconazole granules and injection in pediatric patients]. The Japanese journal of antibiotics, 1994, Volume: 47, Issue:3 Topics: Administration, Oral; Adolescent; Aspergillosis; Candidiasis; Child; Child, Preschool; Female; Fluco	1994
[A multiple center clinical trial on fluconazole for deep-seated fungal infections]. Zhonghua nei ke za zhi, 1995, Volume: 34, Issue:12 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Aspergillosis; Candidiasis; Child; Fe	1995
Fungal colonization and invasive fungal infections following allogeneic BMT using metronidazole, ciprofloxacin and fluconazole or ciprofloxacin and fluconazole as intestinal decontamination. Bone marrow transplantation, 2000, Volume: 26, Issue:9 Topics: Adolescent; Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antifungal Agents; Aspergillosis;	2000
Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy. The American journal of medicine, 2002, Apr-01, Volume: 112, Issue:5 Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Bone Marrow Transplantation; Candidiasis;	2002
Efficacy of fluconazole in the treatment of systemic fungal infections. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1992, Volume: 11, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspergillosis; Candidiasis; Female; Fluconazole; Fungemi	1992
[Clinical study of fluconazole on deep-seated fungal infections]. The Japanese journal of antibiotics, 1989, Volume: 42, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Aspergillosis; Candidiasis; Child; Cl	1989